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Background: The sensing of nutrients by the small intestine generates signals, including the 
secretion of gastrointestinal (GI) hormones, which are important determinants of subsequent 
energy intake and postprandial glycaemia. Recent studies have identified that specific free 
fatty acid (FFA) and sweet taste sensors/receptors, localised to enteroendocrine cells and/or 
absorptive cells, in the small intestine, play a central role in mediating nutrient-induced GI 
hormone release. Furthermore, studies in knock-out (KO) and diet-induced obese (DIO) 
animal models have revealed that altered expression of a number of these receptors 
attenuates GI hormone secretion, and consequently alters food intake and glycaemic control, 
thereby, providing evidence that intestinal nutrient sensing plays a significant role in the 
pathophysiology of obesity and type 2 diabetes (T2D). However, our understanding of the 
relationships between expression of nutrient receptors in the small intestine, nutrient-induced 
release of GI hormones, appetite regulation, and glycaemic control in human health and 
metabolic conditions such as obesity and T2D remains limited.  
 
Aims: The studies presented in this thesis aimed to characterise the expression and 
functional role of duodenal nutrient sensors for fats and carbohydrates in human health, 
obesity and T2D. Specifically, the aims were to investigate: 
1) The effect of acute intraduodenal (ID) nutrient exposure (lipid or glucose) on 
duodenal nutrient sensor expression. 
2) Relationships between the expression of nutrient sensors at baseline (fasted), and 
after nutrient infusion, with the secretion of GI hormones involved in regulating 
appetite, energy intake and glycaemia. 
 
XV 
3) Relationships between the expression of nutrient sensors at baseline (fasted), and 
after nutrient infusion, with appetite perceptions, habitual energy and macronutrient 
intakes. 
 
Methods: For the studies presented in Chapter 3 and 4, 57 volunteers classified as lean (n 
= 20, body mass index (BMI) 18-24 kg.m2), overweight (n = 18, BMI 25-29 kg.m2) or obese 
(n = 19, BMI ≥ 30 kg.m2) underwent unsedated endoscopy. Duodenal biopsies were 
collected at baseline (following a 12 hour fast), and 30 min after an ID infusion of 10% 
Intralipid® (2 kcal/min). Duodenal expression of free fatty acid receptor 1 (FFAR1), FFAR4, 
G-protein coupled receptor 119 (GPR119), and the cluster-of-differentiation-36 (CD36) was 
assessed by quantitative reverse-transcription polymerase chain reaction (RT-PCR), relative 
to expression of the housekeeper gene β-2 microglobulin (β2M). On a separate visit, the 
effects of a 120 min ID infusion of Intralipid® (2 kcal/min) infusion on blood glucose, and 
plasma cholecystokinin (CCK), glucagon-like peptide-1 (GLP-1), glucose-dependent 
insulinotropic peptide (GIP), peptide-YY (PYY), insulin and leptin concentrations were 
evaluated, followed by an ad libitum buffet-meal, from which energy and macronutrient 
intake was quantified. Habitual dietary intake was assessed using food frequency 
questionnaires (FFQs).  
 
For the study presented in Chapter 5, 12 healthy control individuals (HC), 12 patients with 
well-controlled T2D (WC-T2D; HbA1c 6.3 ± 0.2%), and 9 patients with poorly-controlled 
T2D (PC-T2D; HbA1c 10.6 ± 0.5%) undertook an oral glucose tolerance test (OGTT) 
following an overnight fast, as previously described1. These participants were then studied 
during a euglycaemic clamp (5 ± 1 mmol/L), with duodenal biopsies collected at baseline 
(fasted) and after a 30 min ID glucose infusion (4 kcal/min). Copy numbers of taste receptor 
type 1, member 2 (T1R2), the sodium-glucose co-transporter 1 (SGLT-1) and glucose-
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transporter 2 (GLUT2) transcript were assessed at t = 0, 10 and 30 min by RT-PCR. Plasma 
concentrations of GIP, GLP-1, and C-peptide were measured at 10 min intervals from 
baseline (t = 0 min) for 60 min (t = 60 min). Plasma concentrations of 3-ortho-methylglucose 




Duodenal fatty acid sensing receptor expression in lean, overweight and obese 
individuals 
During fasting, duodenal expression of FFAR1 and FFAR4 was lower (P ≤ 0.05), and CD36 
higher (P ≤ 0.001), in obese, compared with lean and overweight, participants. ID lipid 
increased GPR119 and FFAR1 transcript levels independent of BMI (both P ≤ 0.05), while 
levels of CD36 and FFAR4 did not change. The lipid-induced change in FFAR1 was 
positively associated with the incremental area under the curve (iAUC) of GIP (r = 0.3, P ≤ 
0.05). ID lipid induced the secretion of GIP, GLP-1, CCK, PYY and insulin, but there was 
no relationship between hormone levels with fat sensor expression. There was no 
relationship between acute energy and macronutrient intake at the buffet-meal and duodenal 
expression of fat sensors, however, habitual consumption of polyunsaturated fatty acids 
(PUFAs) was negatively associated with GPR119 in healthy, lean participants (r = -0.5, P ≤ 






Duodenal sweet taste receptor (STR) and glucose transporter expression in health, and 
patients with well- and poorly-controlled type 2 diabetes 
Blood glucose concentrations were higher in PC-T2D than WC-T2D and HC groups before 
and during the OGTT (P ≤ 0.001). Basal T1R2 transcript levels were similar across groups, 
while SGLT-1 transcripts were lower in PC-T2D than in the WC-T2D group (P ≤ 0.01), and 
GLUT2 transcripts lower in PC-T2D than in both WC-T2D and HC groups (P ≤ 0.01). 
Plasma GIP concentrations were higher in WC-T2D than in the HC group at baseline (P ≤ 
0.01), with no group differences in GLP-1 and C-peptide concentrations. ID glucose 
increased SGLT-1 and decreased GLUT2 transcripts at 10 min (group × time interaction) in 
both HC and WC-T2D groups (both P ≤ 0.001, P ≤ 0.05 respectively), but had no effect on 
SGLT-1 or GLUT2 transcripts in the PC-T2D group. T1R2 transcripts were lower in PC-
T2D at 10 min than in the WC-T2D group (P ≤ 0.05), while transcript levels of all targets 
were similar across groups at t = 30 min. ID glucose increased plasma GIP, GLP-1 and C-
peptide concentrations (all P ≤ 0.001), with GIP higher in PC-T2D (iAUC, P ≤ 0.05) than in 
the HC group, GLP-1 higher in WC-T2D than the HC group (P ≤ 0.05), and C-peptide 
highest in HC compared to both WC-T2D and PC-T2D groups (P ≤ 0.01, P ≤ 0.001). T1R2 
and GLUT2 transcripts at baseline, and in response to ID glucose, were unrelated to GIP, 
GLP-1 or C-peptide iAUC.  GIP concentrations after 10 min were negatively associated with 
basal SGLT-1 transcripts (r = -0.6, P ≤ 0.05), and the degree of change in SGLT-1 during 
ID glucose (r = -0.5, P ≤ 0.05). Serum 3-OMG at 30 min was positively related to the change 
in T1R2 transcript level at 10 min in HC participants (r = 0.7, P ≤ 0.05) (Chapter 5). 
 
Conclusions: These studies have identified notable differences in the duodenal expression 
of the FFA sensors FFAR1, FFAR4 and CD36 in human obesity at baseline. GPR119 was 
linked to habitual PUFA consumption in health, indicating that dietary fatty acid 
composition, rather than high-fat diet (HFD) consumption per se, may influence fat sensor 
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expression. Overall, the response of FFA sensors to acute ID lipid remained intact in obesity, 
with BMI-independent increases in FFAR1 and GPR119, but no association between FFA 
sensor expression and fat-induced secretion of gut hormones across the cohort. In separate 
studies we demonstrated that baseline expression of duodenal glucose transporters SGLT-1 
and GLUT2 was lower in PC-T2D patients at euglycaemia. Incretin and transcriptional 
responses to glucose infusion, and 3-OMG absorption, was similar in WC-T2D and HC, 
however, PC-T2D patients showed a dysregulated T1R2 response, lack of transcriptional 
change in SGLT-1 and GLUT2 to ID glucose infusion, and exaggerated GIP secretion and 
3-OMG absorption. Therefore, impaired glycaemic control in PC-T2D patients may be 
linked to impairment of luminal sweet sensing and its downstream signals. Further 
investigations are needed to define the functional connections between altered GI nutrient 
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Obesity (BMI ≥ 30 kg.m2) is a prevailing condition in westernised societies, and is associated 
with a number of co-morbidities, which significantly impact both individual and population 
health. The global prevalence of obesity has doubled since 19802. Although a complex 
interplay of factors, including genetics, contribute to the development of obesity, lifestyle 
factors, including the consumption of energy-dense diets, high in fats and sugars, and 
increasingly sedentary lifestyles, have undoubtedly contributed to the current epidemic3,4. 
While there is a desperate need to prevent and treat obesity and its serious co-morbidities, in 
particular T2D, the underlying pathophysiology of these metabolic conditions remains 
unclear, limiting the long-term efficacy of current therapeutic interventions.  
 
Lifestyle interventions (i.e. calorie restricted diets and exercise) are the first line therapy for 
obesity, yet weight loss is often modest, and a lack of compliance presents issues with long-
term effectiveness. Additionally, metabolic adaptations to weight loss can also occur, 
making caloric restriction and weight loss difficult to maintain5. Pharmacological 
interventions can result in modest weight reductions, however these are not maintained long-
term and are often associated with significant side effects. Currently, Roux-en-Y gastric 
bypass surgery (RYGB) is the most effective surgical treatment for obesity6,7, and is 
commonly associated with rapid remission of T2D8. Importantly, the effectiveness of RYGB 
is associated with changes in the secretion of specific hormones from the GI tract which 
regulate satiety, energy intake and glycaemia. Therefore, it is of substantial interest to 
understand the mechanisms governing the secretion of these GI hormones, as they may 
present novel targets for the development of therapies which could mimic the effectiveness 
of RYGB.  
 
It has recently been shown that the GI tract is equipped to detect and respond to ingested 
nutrients via intestinal ‘taste’ sensors on enteroendocrine cells. Changes in the expression or 
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function of these intestinal taste systems in mammals (e.g. genetic KO models, human 
polymorphisms) attenuates the effects of fats and carbohydrates on GI hormone secretion, 
appetite and energy intake, and glycaemia. While the existence of these GI sensors has been 
established in rodents, there are limited human studies. Chapter 2 comprises a 
comprehensive review of the current state of knowledge of oral and intestinal fatty acid and 
sweet taste sensors in health, obesity, and T2D.  
 
The study presented in Chapter 3 characterised the expression of duodenal FFA sensors in 
health, during fasting, and following an acute ID lipid infusion. Examination of relationships 
between fat sensor expression and GI hormone secretion, appetite, and acute energy and 
macronutrient intake in response to lipid was also undertaken. Relationships between 
habitual dietary intake and fat sensor expression were examined to determine whether 
dietary patterns influenced intestinal fat sensitivity. Chapter 4 extended this investigation, 
to determine whether expression of fat sensors was 1) altered in obese individuals, and 2) 
responded differently to an acute lipid stimulus compared to responses in healthy 
individuals. Relationships between transcriptional changes of fat sensors with GI hormone 
secretion, appetite, and energy intake were also assessed to evaluate whether changes in fat 
sensors influenced these events.  
 
Chapter 5 focussed on the intestinal sweet taste system, and whether changes in the 
regulation of intestinal glucose sensing and transport had the potential to impact on control 
of glycaemia in patients with T2D. We previously showed that transcriptional regulation of 
the intestinal sweet taste system was similar in healthy individuals and patients with diet-
controlled T2D at ‘normal’ glycaemic levels (euglycaemia), but was dysregulated in the 
latter when blood glucose levels were elevated (hyperglycaemia). In the hyperglycaemic 
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state, patients with T2D also showed an exaggerated glucose absorption, and worsened 
postprandial glycaemia.  It is unknown, however, whether the sweet taste system is more 
profoundly altered as T2D progresses, in patients who have prevailing hyperglycaemia due 
to ‘poorly’ managed disease. This study, therefore, aimed to characterise transcriptional 
regulation of duodenal sweet taste receptors (STRs) and glucose transporters SGLT-1 and 
GLUT2 in healthy individuals, and patients with ‘well’ or ‘poorly’ controlled T2D, in 
response to ID glucose infusion at euglycaemia. As patients with T2D are known to have an 
increased capacity for glucose absorption, and may show changes in their glucose-dependent 
release of incretin hormones which govern postprandial glycaemia, these factors were 
investigated in healthy individuals and patients with different degrees of T2D control in 
association with transcript changes.  
 
The studies presented in this thesis provide novel information regarding intestinal nutrient 
sensors for fats and carbohydrates in healthy individuals, and individuals with metabolic 
diseases (obesity and T2D). The studies explored the relationships between both fasting, and 
nutrient-stimulated changes in these nutrient sensors, and subsequent GI signalling 
regulating appetite, energy intake, and glycaemic control.  
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The human body has evolved with a disposition for nutrient storage, allowing for periods of 
irregular food availability and famine. In contrast, the modern diet is characterised by 
excessive consumption of fats and sugars, resulting in a surge in the rates of obesity and 
T2D. Although these metabolic disorders arise from a complex interaction of genetic, social, 
and environmental factors, evidence now points to fundamental changes in nutrient 
metabolism at the cellular level contributing to the underlying pathology. Taste receptors 
detect nutrients in the oral cavity and GI tract and can influence the hormonal response to 
nutrients; they may also become maladaptive in conditions of excess fat or sugar 
consumption. Precise links between taste receptor activity, and downstream effects on 
energy intake and glycaemia are not well defined. This review outlines the candidate taste 
receptors for carbohydrates and fats in the oral cavity and within the small intestine, 
highlighting the contributions of underlying genetics (polymorphisms) and sensory 
challenges (e.g., HFD) to the development of obesity and T2D. 
  




Fats and sugars activate reward pathways in the brain that elicit pleasant taste and hedonistic 
sensations, enhance palatability, reinforce taste preference, and promote consumption9-12. 
Humans have developed an innate preference to consume fats and sugars in energy-dense 
foods and then to store energy (lipids, glycogen), limit glucose utilisation, and preserve 
protein in preparation for periods of irregular food availability9. However, in today’s 
environment, energy-dense, high-fat, and high-sugar foods are readily available; in the 
absence of periods of food scarcity, the innate human preference for these foods promotes 
excess energy intake and the development of obesity and its comorbidities (cardiovascular 
disease, hypertension, stroke, osteoarthritis, dyslipidaemia13), most notably, T2D14 (as 
reviewed by Cordain et al.4). It has been proposed that sensory challenges such as a high-fat 
or high-sugar diet may trigger maladaptation of the homeostatic mechanisms of nutrient 
detection and energy regulation in the GI tract. Significant evidence now points to 
fundamental changes in cellular nutrient metabolism as the potential source of 
maladaptation, although the specific mechanisms involved are poorly defined. 
 
The GI tract generates powerful signals that act pre- and postprandially to regulate energy 
intake and glycaemia via modulation of food selection, digestion, and absorption15. Food 
selection is driven through a combination of sensory inputs that include sight, smell 
(olfactory), texture (trigeminal), and taste (gustatory) cues, as well as post oral GI cues. Taste 
receptors on both the lingual and olfactory epithelium form the front line of sensory input to 
the GI tract and detect the chemical composition of ingested foods to provide key sensory 
inputs in order to determine those that are of nutritional benefit (e.g., sugar, fat, protein) and 
those that present risk, such as toxic compounds (e.g., bitter, sour). A large number of animal 
and human studies have established that taste receptors, analogous to oral taste receptors, are 
found throughout the length of the GI tract, where they detect the presence of 
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monosaccharides, FFAs, and peptides/amino acids and trigger the release of the key 
hormones that regulate satiety and glycaemia from the gut wall (see review by Depoortere16). 
The present review highlights the emerging evidence for a role of these GI taste receptors 
for sweet and fat in the regulation of energy intake and glycaemia, as well as the mechanisms 
underlying their role, while acknowledging that present understanding of the precise 
intracellular mechanisms that link GI taste receptors to hormone release and downstream 
effects is rapidly evolving. 
 
Significant research is currently dedicated to uncovering the mechanisms of nutrient 
detection in health and potential dysregulation or maladaptation in metabolic diseases. In 
order to expand present knowledge in this area, an understanding of how the form and/or 
function of taste receptors may be altered in metabolic disease states is of critical importance. 
The relative contributions of underlying genetic predispositions (e.g., receptor 
polymorphisms) or environmental influences such as chronic exposure to a HFD or excess 
consumption of sugars and artificial sweeteners to changes in oral or GI nutrient receptors 
remains to be established. 
 
This review provides a brief overview of GI signals that regulate energy intake and 
glycaemia as well as a summary of oral and small intestinal receptors for sweet and fat taste. 
For each of these taste modalities, functionality in health, obesity, and T2D is compared, as 
is the contribution of sensory challenges (e.g., high-fat and high-sugar diets or non-caloric 
sweeteners) and functional maladaptation (e.g., polymorphisms) of these sensor systems to 
these metabolic conditions. Importantly, how these nutrient sensors may serve as novel 
targets for therapeutic benefits in the settings of obesity and T2D is highlighted. 
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2.3 Gastrointestinal signals critically control energy intake and glycaemia  
GI signals triggered in response to a meal are critical in the regulation of subsequent food 
intake, and the efficient coordination of nutrient digestion, absorption, and subsequent 
utilisation in the body17. Satiation signals are initiated at two sites – in the stomach, largely 
through gastric distension and activation of gastric mechanoreceptors, and in the small 
intestine, upon nutrient-dependent release of peptides from enteroendocrine cells within the 
gut wall17. Other cell types such as brush cells (tuft cells) may also contribute to luminal 
chemosensing18; however, understanding of the role of these cells is limited, and a 
comprehensive discussion is beyond the scope of the current review. Signals arising from 
the small intestine also determine the rate of gastric emptying and are major determinants of 
the postprandial glycaemic response; it is, therefore, critical to understand how nutrient 
sensors and their effectors in the small intestine function in a state of health as well as their 
potential for maladaptation in disease. 
 
2.4 Effects of gastrointestinal hormones on satiation and glycaemia  
More than 20 different hormones are released by specific populations of small intestinal 
enteroendocrine cells in response to ingested nutrients (as reviewed by Rindi et al.19). These 
hormones modulate a variety of GI functions, including pancreatic secretion, motility, 
glycaemia, and, importantly, energy intake and satiety18. Key gut hormones involved in the 
satiety response include CCK derived from I-cells20, and GLP-1 and PYY from L-cells21,22. 
Traditionally, each GI hormone was viewed as being secreted from a specific cell type; 
however, there is now evidence of considerable overlap in hormone expression between I-, 
K, and L-cells, with enteroendocrine cells co-expressing numerous functionally related 
peptides23. This suggests that a single cell type may be tuned to secrete specific hormones 
depending on the cells’ location along the axis of the gut and their exposure to specific 
Literature Review  Chapter 2 
 
11 
dietary components. Further studies in this area will be critical to determine the factors that 
control the phenotypes of enteroendocrine cells along the axis of the intestine. CCK, GLP-1, 
and PYY work to modulate GI motility, appetite, and energy intake, and they slow the rate 
of gastric emptying. GLP-1 in conjunction with K-cell-derived GIP acts as an incretin 
hormone to substantially augment insulin secretion when glucose is given orally, compared 
to as an isoglycaemic intravenous (IV) infusion24. By contrast, ghrelin, the best known 
orexigenic hormone, is produced in enteroendocrine cells of the gastric mucosa; it 
powerfully stimulates food intake in humans25, increases motility, and decreases insulin 
secretion26. 
 
It is now well established that intestinal taste receptors can trigger the release of CCK, PYY, 
GLP-1, and GIP27-30, which supports a link between taste receptor expression and/or 
functionality and the control of energy intake and/or glycaemia. To date, there is limited 
knowledge regarding a link between nutrient-induced ghrelin suppression and taste receptor 
activation, with available functional evidence highlighting α-gustducin activity linked to 
bitter receptor activation in ghrelin- releasing cells in the stomach31. The focus of the current 
review is on the localisation and characteristics of sweet and fat taste receptors in the tongue 
and small intestine, as well as their links with GI hormone release from open enteroendocrine 
cells. The review also documents recent evidence of how these sweet and fat taste receptors 
may be dysregulated in metabolic disease states, such as in obesity and T2D (Table 2.1)1,3, 
27-29, 32-65.   
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Table 2.1: Candidate free fatty acid (FFA) and sweet taste receptors (STRs) in the gastrointestinal (GI) tract: their location, GI mediators and 
physiological responses to metabolic challenge and genetic knockout (KO). 
Abbreviations: circumvallate (CV); long-chain fatty acid (LCFA); glucagon-like peptide-1 (GLP-1); glucagon-like peptide-2 (GLP-2); peptide tyrosine 
tyrosine (PYY); cholecystokinin (CCK); high-fat diet (HFD); glucose-dependent insulinotropic peptide (GIP); knockout (KO); oleoylethanolamide (OEA); 
type 2 diabetes (T2D); sodium-glucose co-tranporter-1 (SGLT-1) 
Gene and reference Location Example of ligands Gastrointestinal mediator 
Physiological response to 
HFD/obesity/T2D 
Physiological change in 
response to genetic KO 
FFAR4 
Matsumura et al. (2007)32; Martin et al. 
(2012)33; Cartoni et al. (2010)34; Hirasawa et al. 
(2005)28; Ichimura et al. (2012)35; Duca et al. 
(2013)36; Kawai et al. (2003)37; Tanaka et al. 
(2008)27 
Oral: CV, foliate, fungiform papillae32-34 
Small intestine: enteroendocrine L 
cells28 
Unsaturated LCFA28, 33 GLP-128, PYY28,CCK27 
HFD: 
↓protein expression36 






Cartoni et al. (2010)34; Itoh et al. (2003)38; 
Edfalk et al. (2008)39; Liou et al. (2011)40; Lan 
et al. (2008)41; Steneberg et al. (2005)42; Latour 
et al. (2007)43; Briscoe et al. (2003)44; Kebede 
et al. (2008)45 
Oral: CV, foliate, rarely fungiform34 
Small intestine: enteroendocrine L and 
K cells39 
Pancreas: pancreatic β cells38 
Saturated and unsaturated 
medium- and LCFA34 
 
GLP-139, GIP39, CCK40 














↔fasting blood glucose43 
GPR119 
Lauffer et al. (2009)46; Lan et al. (2009)47; 
Overton et al. (2006)48; Hansen et al. (2012)49; 
Chu et al. (2008)50 
Small intestine:  
enteroendocrine L cells46 
Pancreas: pancreatic β cells47 
OEA48, 2-oleyl glycerol, 2-
monoacylglycerols49   
GLP-147, 50, GIP50  ↓GLP-146 
CD36 
Laugerette et al. (2005)3; Simons et al. 
(2011)51; Drover et al. (2005)52; Zhang et al. 
(2011)53; Poirier et al. (1996)54; Lobo et al. 
(2001)55; Schwartz et al. (2008)56 
Oral: CV, foliate3, 51 
Small intestine: brush border of 
enterocytes54, 55 
Saturated and unsaturated 
LCFA (C≥ 16)3, OEA56 
OEA56 
HFD: 
↓CV transcript expression53 
↓Fat taste preference3; 
 hypertriglyceridaemia52;  
↓OEA mobilisation in response 
to fat56 
T1R2/T1R3 
Nelson et al. (2001)57; Margolskee et al. 
(2007)58; Jang et al. (2007)59; Dyer et al. 
(2005)60; Young et al. (2009)61; Young et al. 
(2013)1; Daly et al. (2012)66 
Oral: CV57 
Small intestine: 
enteroendocrine I and K cells1, 59-61 
Sugars, d-amino acids, sweet 
proteins, non-caloric 
sweeteners (e.g., saccharin58, 
acesulfame-k58)57 
GLP-158, 59, GIP58, GLP-266 
T2D vs healthy1: 
↔T1R2 transcript at baseline; 
↑T1R2 by luminal glucose at 
euglycaemia, ↓at hyperglycaemia 
(healthy); 
↑by luminal glucose in T2D 
irrespective of glycaemia (T2D) 
↑glucose absorption at 
hyperglycaemia 
T1R3/α-gustducin KO58: 
↔SGLT-1 transcript on low or 
high-carbohydrate diet;  
↔SGLT-1 transcript or protein 
in response to dietary non-
caloric sweeteners 
SGLT-1 
Yoshida et al. (1995)62; Gorboulev et al. 
(2012)63; Dyer et al. (2002)64; Margolskee et al. 
(2007)58; Stearns et al. (2010)65; Moran et al. 
(2010)29 
Small intestine: brush border membrane 
of enterocytes62, 64 
Substrates: D-glucose29, 65, D-
galactose 
Inducing ligands: D-fructose58, 
saccharin29, 58, 65, sucralose58 
GLP-158, GIP67 
T2D: 
↑transcript and protein 




↓glucose-mediated GIP and 
GLP-1 secretion63 
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2.5 Gastrointestinal taste receptors 
Well-developed knowledge of oral taste receptors has enabled rapid advances in 
understanding the intestinal nutrient-sensing mechanisms following the identification of 
so-called GI taste receptors in the intestine. The recognition of morphological and 
phenotypic similarities between lingual taste cells and intestinal enteroendocrine cells has 
refocused research efforts towards understanding the mechanisms by which intestinal 
enteroendocrine cells sense nutrients and initiate signalling to regulate food intake and 
glycaemia. Both cell types are polarised and possess apical microvilli exposed to the lumen 
that are equipped with specific G protein-coupled receptors (GPRs) tuned to individual taste 
modalities. These receptors detect sweet, sour, salty, bitter, and umami tastants, as well as 
fatty acids, and, in turn, activate intracellular signalling pathways comprised of ion channels, 
ligand-gated channels, and enzymes, leading to the release of specific mediators at their 
basolateral membrane68. These mediators then act in an autocrine, paracrine, or endocrine 
fashion, and can activate cognate receptors on adjacent sensory nerve endings to initiate 
signalling to brain centres68. Activation of oral taste receptors and lingual afferents elicits a 
conscious perception of taste, and, via higher brain centres, generates immediate and critical 
response mechanisms driving food selection and avoidance69. Activation of intestinal taste 
receptors does not elicit a conscious perception of taste; however, the capacity of these 
receptors to trigger hormone release and activate gut-brain signalling pathways via the vagus 
nerve significantly contributes to the generation of meal-related sensations70. 
 
2.6 Sweet sensing in the gastrointestinal tract  
2.6.1 Sweet taste receptors in the oral epithelium 
Sweet tastants are detected by a heterodimer of the GPR subtypes T1R2 and T1R3, which 
acts as a broadly tuned receptor for sugars, D-amino acids, sweet proteins, and non-caloric 
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sweeteners1,57-61,66. Studies focused on the oral sweet taste receptor heterodimer have 
demonstrated multiple binding sites for non-caloric sweeteners, supporting broad tuning of 
STRs to structurally diverse stimuli71. Interaction of sweet tastants with oral sweet taste 
receptors leads to activation of the taste-specific G protein, α-gustducin60, and in turn, to a 
rise in intracellular calcium and the gating of a taste-specific transient receptor potential ion 
channel, transient receptor potential cation channel subfamily M member 5 (TRPM5)72. 
Gating of this channel facilitates cell depolarisation, the basolateral release of mediators, 
including noradrenaline, acetylcholine, serotonin and glutamate, and activation of inputs 
from the lingual afferent nerves to the nucleus of the solitary tract in the brainstem to 
generate the perception of sweet taste68,73. 
 
2.6.2 Oral sweet taste receptors and sweet taste preference 
Preference for sweet substances is thought to be inherent rather than learnt. Newborns 
demonstrate the ability to differentiate varying degrees of sweetness and consume greater 
volumes of solutions that taste sweeter74. Many factors influence food preferences, and even 
flavours from the maternal diet transmitted through breast milk can influence early food 
preference75. Although the positive hedonic responses to sweet taste are a universal trait, 
substantial inter-individual variation in the perceived intensity of, and preference for, 
sweetness has generated significant interest in the field of sweet taste sensing. Although links 
between sweet taste preference and BMI are not consistently observed76, there is evidence 
to support a heightened preference for sweet substances in obesity, which may drive the 
consumption of excess calories77. Interestingly, obese individuals who have undergone 
RYGB have an enhanced oral perception of sweetness and reduced desire to consume 
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high-carbohydrate (and high-fat) foods78,79. However, the extent to which these changes 
involve modifications in intestinal STR expression or function requires further investigation.  
 
2.6.3 Sweet taste receptor polymorphisms and sweet taste perception 
A number of STR polymorphisms have been identified in humans80,81 (see Table 2.2)35, 80-88. 
For example, two single-nucleotide polymorphisms (SNPs) located upstream of the 
promoter region of T1R3 are strongly associated with reduced oral sucrose sensitivity in 
humans81. These SNPs resulted in reduced levels of T1R3 transcripts in vitro; however, care 
must be exercised in interpretation of this finding, as the study used bile-duct derived cells, 
which may have different proteins interacting at this promoter region89. Further evidence of 
the effects of polymorphisms on sweet taste perception comes from a worldwide survey of 
human polymorphisms in the T1R receptor family (T1R1, T1R2, T1R3), which revealed that 
T1R2 is highly diverse compared to other  human genes; this corresponds with the variability 
seen in sweet taste thresholds amongst humans90. Importantly, the majority of amino acid 
variants occur in the first extracellular domain of T1R receptors, the domain that contains 
the ligand-binding site for carbohydrates. Further investigation is needed to determine the 
role of STR polymorphisms in driving preference for sweet foods and whether 
polymorphisms in gut STRs have functional implications for food selection and metabolic 
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Table 2.2: Characteristics of commonly described polymorphisms of fatty acid and sweet sensors in the human GI tract 
Gene and reference Polymorphism Region Population Physiological effects 
FFAR1 
Hamid et al. (2005)82 
 

























Danish Caucasians (T2D and 
healthy) 





Sicilian (healthy and obese) 
↔Insulin response (OGTT) 
↔Allele frequency between T2D and glucose-tolerant controls 
 
His/His>Arg/Arg: 




↑Allele frequency with ↑BMI; transfection of variant in HeLa cells alters 
FFAR1 function resulting in ↓ability to sense lipids, impaired Ca2+ release 
and β-cell secretion in a model of insulin secretion 
FFAR4 






European (healthy and obese) 
↓Receptor expression in human intestinal NCI-H716 cells with ↓GLP-1 
release, ↑risk of obesity and insulin resistance 
CD36 
Pepino et al. (2012)85 
 
 
Keller et al. (2012)86 
 
 















































White European (non-diabetics 
at risk for T2D) 
 
 
Oral threshold for oleic acid and trinolein: GG>AG>AA85 
 
 
↔Food consumption, fat preference85, 
↑preference for fat (AA genotype) 86 
 






↑Waist circumference (rs3211883, rs3211908),  
↔insulin sensitivity, 
↔hepatic lipid accumulation 
T1R2 
Eny et al. (2010)80 
 











domain and ligand 
binding site 
 
White, South Asian, East 
Asian, other (healthy and 
T2D) 
 
White, South Asian, East 











Fushan et al. (2009)81 
rs307355, rs35744813 Upstream of T1R3 
coding sequence 
European, Asian, African ↓Sensitivity to sucrose 
Abbreviations: BMI, body mass index; GLP-1, glucagon-like peptide-1; OGTT, oral glucose tolerance test; T2D, type 2 diabetes
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2.6.4 Sweet taste receptors in the intestinal epithelium 
2.6.4.1 Functional evidence for a role for sweet taste receptors in incretin 
hormone release 
STRs have been localised to subpopulations of enteroendocrine cells within the proximal 
small intestine of mice and humans, which is a key region of nutrient detection1,59-61,91-93. 
Co-localisation of α-gustducin and GLP-1 within the L-cells of the mouse duodenum 
provides evidence for a functional relationship between activation of the STR-gustducin 
pathway and subsequent incretin release94. Importantly, animals that lack either α-gustducin, 
or the T1R3 subunit, demonstrate major defects in glucose-mediated GLP-1 secretion and 
disrupted glucose homeostasis59,94. This provides the strongest functional evidence for a role 
of the STR-gustducin-coupled pathway as a significant contributor to overall glycaemic 
control. 
 
The human L-cell line NCI-H716 expresses all components of the sweet taste pathway. 
Administration of glucose and the non-caloric sweetener sucralose in one study induced 
GLP-1 secretion, an effect that was inhibited by both RNA interference of α-gustducin, and 
the sweet taste receptor inhibitor lactisole59. In a seminal study of 35 healthy volunteers, 
Gerspach et al.30 also demonstrated that glucose-dependent GLP-1 release was attenuated in 
the presence of lactisole, providing direct evidence of a functional role of intestinal sweet 
taste receptors in the regulation of incretin hormone release. In this study, lactisole reduced 
the GLP-1 and PYY response to intragastrically and intraduodenally administered glucose 
and mixed-nutrient loads, but the effect was greater following intragastric administration. 
The prominent effect of lactisole from the gastric compartment was unexpected, particularly 
given that the highest STR expression in humans occurs within the duodenum and since 
gastric emptying was not altered by lactisole. STR expression was not directly measured in 
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this study; however, an important point to note is that STR transcript expression is rapidly 
downregulated in mice receiving jejunal glucose infusion61. Accordingly, reduced STR 
availability to luminal stimuli in the study of Gerspach et al.30 may have affected the 
subsequent release of GLP-1. As it is not known whether lactisole antagonism affects the 
regulation of STR expression, this possibility must be considered. The effect of lactisole on 
GLP-1 release may also occur via an indirect mechanism that utilises hormones released 
from the stomach. T1R3 has been localised to gastric brush cells95, and may trigger hormonal 
or neural pathways to stimulate satiation peptide release in the intestine. The potential 
interaction between gastric and intestinal signalling mechanisms is an area that requires 
further investigation. 
 
2.6.4.2 Effects of intestinal sweet taste receptor activation on glucose 
transporter availability 
Landmark studies in animals have provided strong evidence for a link between intestinal 
STR activation and an increase in levels of the primary intestinal glucose transporter, 
SGLT-1, as well as luminal substrate transport capacity29,58,65. SGLT-1 is located in the brush 
border membrane (BBM) of enterocytes in the proximal intestine, and in addition to an 
absorptive role, the apical transport of sugars by SGLT-1 is also an important determinant 
of intestinal “incretin” release in both rodents and humans. Rodents administered 
intraluminal phloridzin (a competitive inhibitor of SGLT-1) show attenuated incretin 
responses to sweet stimuli96, while mice deficient in SGLT-1 do not have an effective first 
phase GLP-1 response, which involves glucose-mediated insulin secretion and inhibition of 
hepatic glucose production63. Intracellular glucose diffuses into the bloodstream via the 
facilitative transporter GLUT2 at the basolateral membrane of enterocytes97. While early 
rodent studies indicated that GLUT2 was translocated to the apical surface in the presence 
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of luminal sugars93, recent studies have indicated that GLUT2 translocation does not occur 
following a glucose load in healthy humans63,98. Further work is needed to understand the 
potential role of GLUT2 in taste signal transduction. 
 
Indeed, SGLT-1 expression and function is directed by the presence of luminal sweet 
tastants, and SGLT-1 is upregulated in the presence of a broader range of sweet ligands than 
its substrate specificity, including by non-caloric sweeteners, highlighting the upstream role 
of a broadly-tuned sensor29,58,62,65-98 (see Table 2.1). The upregulation of SGLT-1 in 
enterocytes is known to occur via a cAMP-dependent pathway that involves early 
post-transcriptional stabilisation of SGLT-1 transcripts99. Importantly, intake of dietary 
sugars and non-caloric sweeteners have been shown to increase intestinal SGLT-1 transcript, 
protein and function in wild-type (WT) mice, an effect that is absent in mice lacking the 
sweet taste molecule T1R3 or α-gustducin58. These findings indicate that SGLT-1 levels are 
linked to the broadly-tuned STR, and that intestinal STRs are engaged in the regulation of 
glucose uptake in animals. In this manner, activation of STRs is likely to trigger the release 
of autocrine and/or paracrine signals from taste cells, which may act upon adjacent 
enterocytes, to regulate SGLT-1 expression and function58. Candidate signal mediators 
released include GIP58, GLP-158,59, and GLP-2100-103, which are co-expressed in many of the 
enteroendocrine cells that contain T1R258. Accordingly, STRs have been proposed as the 
intestinal sensor for dietary sweet tastants, with SGLT-1 acting as an important effector1. 
The implications of such a relationship include the potential for therapeutic targets that can 
specifically work to enhance, or reduce, carbohydrate transport; this is an issue of critical 
relevance to metabolic diseases, which are characterised by maladaptive carbohydrate 
absorption. 
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2.6.5 Disordered sweet taste receptor expression in type 2 diabetes 
Patients with T2D often show disordered GI responses to nutrients, with frequently delayed 
gastric emptying and a high prevalence of GI symptoms104-106. There are a number of 
abnormalities that may impact intestinal glucose sensing in T2D; secretion of GLP-1 and 
GIP have been inconsistently reported to be diminished in these patients107,108, while 
intestinal levels of SGLT-1 may be increased, thus increasing the capacity for glucose 
absorption64. It was recently demonstrated that the intestinal STR system is reciprocally 
regulated by luminal glucose exposure and blood glucose concentrations in humans. Under 
euglycaemic conditions, ID glucose infusion increased intestinal expression of T1R2, while 
the same infusion under hyperglycaemic conditions decreased T1R2 levels; this regulation 
may serve to limit SGLT-1 recruitment during hyperglycaemia. However, in patients with 
T2D, T1R2 levels increased upon glucose infusion, irrespective of the prevailing glycaemia, 
while glucose absorption was increased at hyperglycaemia, as seen by an elevation in levels 
of the glucose-absorption marker 3-OMG, a non-metabolisable substrate of SGLT-11. Taken 
together, these results indicate that STR signals persist during hyperglycaemia in T2D 
patients, and, as a consequence, may sustain the availability of SGLT-1 transport and 
augment postprandial hyperglycaemia. The proposed pathways for STR signalling in health, 
and changes that occur in T2D conditions are outlined in Figure 2.1. Therapeutics that block 
STRs, such as lactisole, may therefore improve glycaemic control in the setting of T2D, but 
this hypothesis needs to be directly tested. 
 
Importantly, to date, no studies have directly investigated whether lactisole blockade of 
STRs is capable of modifying glucose absorption in human T2D. Given the presence of 
impaired incretin secretion in T2D, it is of interest to investigate further how STR expression 
and function is altered in this state. Such knowledge is critical in order to determine the 
potential therapeutic benefit of lactisole in the clinical setting. 





Figure 2.1: Generalised model of intestinal sweet taste sensing in healthy individuals 
and those with T2D under hyperglycaemic conditions. Heterodimeric STRs comprising 
the GPR subunits T1R2 + T1R3 detect a wide range of luminal stimuli, such as sugars, 
D-amino acids, and non-caloric sweeteners. Tastants bind to the receptor and activate the 
taste-specific G-protein α-gustducin via subunits Gαq to activate PLC βII or Gαs to stimulate 
cAMP/cGMP-dependent pathway. Upon activation of secondary messengers, calcium is 
released from inositol triphosphate–sensitive intracellular stores, leading to the gating of 
TRPM5. The subsequent influx of sodium and cell depolarisation trigger basolateral 
mediator release of the incretin hormones GLP-1 and GIP or GLP-2, which  enter the blood 
and function as hormones or paracrine signals at adjacent enterocytes to upregulate the 
primary intestinal glucose transporter, SGLT-1. Upregulation of SGLT-1 increases apical 
glucose transport capacity, with intracellular glucose entering the bloodstream via the 
basolateral facilitative GLUT2 transporter. In healthy humans, intestinal STRs are 
reciprocally regulated by luminal glucose according to prevailing glycaemia, i.e., increased 
during euglycaemia, decreased during hyperglycaemia. This may limit SGLT-1 function to 
control postprandial glycaemic excursions. In contrast, in T2D, STR transcript levels 
increase irrespective of prevailing glycaemia, and glucose absorption is increased during 
hyperglycaemia.  
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2.6.6 Activation of sweet taste receptors by non-caloric sweeteners and 
implications for metabolic disease 
Increased consumption of dietary sugars has been linked to the rising incidence of T2D in 
Western populations109. Non-caloric sweeteners have become a topic of much debate. 
Typically considered to be metabolically inert and consumed as a calorie-free sugar 
substitute, non-caloric sweeteners have been marketed as a healthy alternative to nutritive 
sugars as part of a weight loss regimen or for individuals with T2D110, with initial findings 
suggesting benefits relating to body weight and decreased energy intake111. However, recent 
epidemiological data have shown that heavy consumers of beverages sweetened with 
non-caloric sweeteners have an increased risk of developing T2D112. Although further 
research is required, this finding implies that non-caloric sweeteners may not be functionally 
inert and may negatively affect glycaemic control, thereby offsetting any gains due to 
reduced energy intake. 
 
Although evidence is convincing in animal models, human studies have not yet established 
a direct functional role of non-caloric sweeteners. Sucralose, aspartame, and acesulfame-K 
are known to act on intestinal STRs to increase SGLT-1 expression and function in pigs29, 
rats65, and mice58. In studies performed in healthy humans, diet soda containing sucralose 
and acesulfame-K has been shown to significantly increase GLP-1 release and, 
consequently, decrease peak glucose levels when ingested prior to an oral glucose load113,114, 
but the same effects were not observed in T2D patients114. However, these studies did not 
control for other compounds in the soda that may have affected GLP-1 responses. When 
these same doses of sucralose and acesulfame-K were infused together into the duodenum 
of healthy humans, there was no acute effect on gastric emptying, GLP-1 release, or 
glycaemic response following an oral glucose load115. Similarly, other studies have found 
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that non-caloric sweeteners, such as sucralose116-118, saccharin117, aspartame118,  
acesulfame-K118, and stevia117, when administered alone, are not sufficient to modify acute 
in vivo gut hormone secretion119. It has been postulated that the observed increase in GLP-1 
in healthy volunteers potentially requires an adjunct caloric, metabolisable sugar, in addition 
to the non-caloric sweetener, to elicit GLP-1 changes114. It is also notable that circulating 
levels of gut hormones may be a blunt marker for local release based on evidence in rodents, 
whereby non-caloric sweetener triggered gut hormone levels were several orders higher in 
intestinal lymph than in circulation120. Clearly, additional studies are required to elucidate 
the effects of non-caloric sweeteners on GI and metabolic functions, particularly in chronic 
intake settings. 
 
The predominance of non-caloric sweeteners in the modern food supply highlights the 
importance of understanding the specific intracellular pathways activated by individual 
non-caloric sweeteners and their downstream effects110. For example, the non-caloric 
sweetener acesulfame-K can induce glucose uptake in rat intestinal cell lines (Caco-2, RIE-1, 
and IEC-6) at high glucose concentrations by triggering the translocation of GLUT-2 from 
the basolateral to the apical membrane121. The use of a phospholipase βII (PLC βII) inhibitor 
(U-73122) abolished this effect, indicating the importance of PLC βII in mediating enhanced 
glucose uptake via increased STR signalling121. Research in this area is active, yet no 
definitive conclusions have been formed. 
 
It is well established that intestinal STRs are engaged in sweet sensing, and may influence 
glycaemic control; in this, their GI function extends beyond simple nutrient detection in the 
periphery. However, further research is needed to determine the direct effects of STR 
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modification on metabolic disease in response to chronic ingestion, and whether actively 
targeting STRs can be of potential therapeutic benefit for conditions such as T2D. 
 
2.7 Fat sensing in the gastrointestinal tract  
2.7.1 Evidence for oral fat taste in humans 
Recent evidence for the existence of fat taste has profound implications, particularly in the 
setting of the current obesity epidemic. The oral perception of dietary fat has long been 
considered to be based only on texture, odour, and postingestive cues3,122. However, this 
view was challenged by the discovery that triacylglycerols (TAGs), the principal form of fat 
in food, are digested by lingual lipases to release FFAs, which can act as effective stimuli 
for oral fatty acid taste receptors in both rodents and humans37,123. In humans, lipase activity 
is sufficient to liberate FFAs at a detectable range of 0.02–6.4 mM123, and in rats, the addition 
of the potent lipase inhibitor, orlistat, results in a lower preference for dietary TAG intake, 
but not FFAs37, indicating that FFAs are the key stimulus required for oral perception of fat 
“taste.” 
 
2.7.2 Oral sensitivity to fatty acids and fat preference 
Fats are an energy-dense source of nutrition possessing hedonistic qualities through the 
activation of central reward pathways in the brain, enhancing palatability, and reinforcing 
taste preferences10-12. Indeed, a preference for fatty foods is a common trait amongst 
mammals, and a relationship exists between oral sensitivity to fatty acids and fat 
preference124. Rodents spontaneously prefer fatty foods in a free-choice situation, with 
dietary fat preferences inversely correlated with oral FFA sensitivity. For example, when 
placed on a 3-choice macronutrient selection paradigm (protein, carbohydrate, and fat), 
DIO-prone Osborne-Mendel (OM) rats prefer a HFD, and rapidly become obese, compared 
Literature Review  Chapter 2 
 
25 
with DIO-resistant (DIO-R) S5B/PL rats, which are naturally inclined to ingest relatively 
little fat and reduce their total caloric intake when exposed to a HFD in order to stay lean125. 
In humans, studies have shown that when fed a low-fat diet for 4 weeks, both lean and 
overweight/obese individuals have an increased taste sensitivity (i.e., decreased taste 
threshold) to oleic acid (C18:1). Conversely, when consuming a HFD, lean individuals have 
reduced taste sensitivity to C18:1, whereas no change in sensitivity is observed in 
overweight/obese individuals126. Failure of the HFD to alter taste thresholds in the obese 
may be due to a pre-existing adaptation to a HFD, resulting in a greater preference for, and 
increased consumption of, high-fat foods123,126. Indeed, obese subjects have increased fat 
detection thresholds relative to lean individuals127. However, further investigation is needed 
to provide empirical evidence of such an adaptation. As such, understanding the mechanisms 
underlying differences in fat sensitivity, as well as their functional responses, is the next step 
towards determining whether maladaptation of fat sensors may predispose individuals to 
obesity. 
 
2.7.3 Fat taste in the small intestine 
As with STRs, FFA receptors have been localised to the intestine, where they can trigger gut 
hormone release, influencing satiety signals and energy intake27,28,39,46,47. When TAGs are 
infused directly into the duodenum of humans, food intake is significantly reduced, an effect 
that is abolished through addition of the lipase inhibitor tetrahydrolipstatin, highlighting that 
fat digestion (i.e., the release of FFAs) is also an essential requirement for intestinal fat 
sensing21,128. Importantly, in the small intestine, it is long-chain fatty acids (LCFAs) with a 
chain length of 12 carbon atoms that induce the most potent, fat-induced hormone secretion, 
slowing of gastric emptying, and suppression of energy intake129-133. Evidence from rodent 
and human studies supports a relationship between impaired oral receptor-mediated 
fat-sensing, particularly of LCFA, and obesity, potentially driving energy 
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overconsumption123,134. In the same manner, the sensitivity of FFA receptors within the small 
intestine may be impaired in obesity127, leading to overconsumption due to reduced satiety 
signalling. The potential contribution of FFA receptors to satiety signalling is discussed 
further below, and the importance of further investigations into these orosensory processes 
is worth emphasising.  
 
2.7.4 Candidate fatty acid receptors 
Multiple receptors for oral and intestinal FFAs have now been identified. This review is 
focused on the FFAs responsible for the detection of LCFAs, since LCFAs have the most 
potent suppressive effects on GI function and play a critical role in fat-induced satiety 
signalling. The lead GPR candidates include FFAR4 (previously GPR120)27,28,32-36,124, 
FFAR1 (previously GPR40)34,38-45, GPR11946-50, and the multi-functional protein 
CD363,51-56, 86 (Table 2.1). Evidence for the effects of HFD/obesity on the availability and 
function of these receptors is also discussed, with links between receptors and hormonal 
signalling from the small intestine highlighted for their potential influence on subsequent 
energy intake (Figure 2.2). 
 
2.7.5 Fatty acid receptor FFAR4 
2.7.5.1 Oral FFAR4 
FFAR4 is expressed in the circumvallate (CV), foliate, and fungiform taste buds of rats32 
and mice33,34, as well as the lingual taste cells of humans122. FFAR4 KO mice demonstrate 
diminished preference for linoleic and oleic acid, and attenuated lingual nerve responses to 
several fatty acids, with normal responses to other tastants (e.g., sour, salty, umami)34. 
 





Figure 2.2: Generalised model of intestinal fat taste sensing in normal and in high-fat 
diet/obese conditions. FFAs, the breakdown product of dietary TAGs, activate GPRs 
located on the apical surface of small intestinal enteroendocrine cells. LCFAs, potent 
stimulators of GI function, bind to FFA receptors (FFAR4, FFAR1) and activate a 
taste-specific G-protein α-gustducin (Gαq) and a secondary messenger cascade via 
phosphatidylinositol 4, 5-bisphosphate (PIP2) or cAMP (Gαs) in the case of GPR119. PIP2 
is converted to inositol triphosphate via activation of PLC βII, triggering the release of 
calcium from intracellular endoplasmic reticulum stores, gating of cation channel TRPM5, 
and the influx of sodium and cell depolarisation. Basolateral mediators (e.g., CCK, GLP-1) 
are subsequently released and act upon vagal afferents within the gut wall, signalling to the 
brainstem and higher brain centres to regulate satiety via the slowing of gastric emptying 
and subsequent suppression of energy intake. The multifunctional glycoprotein CD36 is 
responsible for uptake of FFAs, and is also critical for the production and/or mobilisation of 
the oleic acid derivative, oleoylethanolamide (OEA), which reduces meal frequency via 
activation of the peroxisome-proliferator-activated receptor-α (PPAR-α) pathway. PPAR-α 
also contributes to the formation of TAG-rich chylomicrons within the endoplasmic 
reticulum and, in particular, the component apolipoprotein A-IV, which potentially mediates 
CCK-induced satiety signalling. The quantity and quality of chylomicron production may 
affect blood clearance, potentially affecting atherogenicity of the chylomicrons produced 
and, in CD36 KO mice, the chylomicrons produced contain less TAG and are much smaller, 
leading to TAG retention in enterocytes, particularly in HFD conditions135. In HFD and 
obesity conditions, it is hypothesised that the increased luminal exposure to FFAs 
downregulates FFAR expression, resulting in attenuated secretion of GI signalling peptides 
and, consequently, impaired fat-induced suppression of gastric emptying and energy intake.  
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FFAR4 co-localises with GLP-1 within a subset of cells that co-express CD36 in the mouse 
CV papillae, and may modulate oral sensitivity thresholds for sucrose and unsaturated 
LCFA33. The addition of oleic or α-linoleic acid to isolated mouse CV papillae triggers a rise 
in active GLP-1 levels, an effect mimicked by the potent FFAR4 agonist, GSK137657A, 
providing evidence of oral FFAR4-mediated GLP-1 release in the signalling of LCFA33. The 
potential involvement of GLP-1 release in the oral detection of LCFA is further suggested 
by the observation that GLP-1 receptor KO mice display a reduced preference  for  oral  
LCFA, and are unable to detect low concentrations of oil (0.02–0.5% w/v)33. 
 
2.7.5.2 Effects of a high-fat diet/obesity on intestinal FFAR4: links to the 
regulation of energy intake 
FFAR4 is expressed on L-cells that release GLP-1 and PYY in the mouse small intestine28. 
While a role for FFAR4 in energy regulation has been demonstrated, the precise mechanisms 
involved remain unclear. For example, rats with HFD-induced obesity have increased levels 
of FFAR4 transcript and protein in the proximal small intestine (duodenum and jejunum), 
but decreased CCK, PYY, and GLP-1 protein expression relative to DIO-R rats36. In 
contrast, in mouse STC-1 cells, which model small intestinal enteroendocrine cells, fatty 
acid-induced GLP-1 release is abolished following silencing of FFAR4 by RNA 
interference27,28. Correspondingly, mice that completely lack FFAR4 receptors demonstrate 
attenuated GLP-1 secretion in response to fatty acid exposure28,35, and on a HFD they 
develop more profound obesity, glucose intolerance, and insulin resistance compared to their 
WT counterparts35. These outcomes indicate a loss of satiety signalling generated through 
FFAR4 activation, and a subsequent attenuation of the suppressive effects of fat on appetite 
and energy intake in the development of obesity and its metabolic comorbidities. 
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The modulation of FFAR4 in obesity is complex and may involve an initial acute response 
to increase FFAR4 to compensate for attenuated satiety signalling from L-cells during a 
HFD. Thereafter, modifications of intracellular and downstream pathways, such as 
post-translational modifications, may occur, leading to a disconnect between FFAR4 
signalling and peptide secretion36. 
 
Current evidence supports a role for FFAR4 receptors in the detection of LCFAs and release 
of GLP-1 in both the oral and intestinal epithelium. Moreover, the potential loss of peripheral 
satiety signalling in FFAR4 KO and DIO rodent models provides strong support for a role 
of FFAR4 in energy regulation. In humans, key information on FFAR4 regulation is awaited, 
with studies to date focused on changes in human cell-lines, which may not necessarily 
reflect the in vivo setting. In order to extrapolate FFAR4 dysregulation to the tendency to 
overeat in obesity, changes at the mucosal level will need to be investigated to determine the 
luminal availability and subsequent function of the receptor. 
 
2.7.5.3 Effect of FFAR4 polymorphisms on receptor function and body weight 
Numerous FFAR4 polymorphisms have been identified in humans; with evidence that these 
genetic variations are linked to BMI35 (see Table 2.2). A loss-of-function variant of FFAR4 
(R270H) has been associated with an increased risk of obesity and insulin resistance in 
European populations35 but to a lesser extent in other populations, such as the Japanese136. 
For example, variant R270H is rare in Japan (1 in 1,585 subjects was a heterozygous carrier) 
but is polymorphic in European populations35; this may explain discrepancies in population-
based analysis. Few studies have evaluated the functional implications of FFAR4 variations; 
however, Ichimura et al.35 reported that LCFA-induced GLP-1 release from human intestinal 
NCI-H716 cells is attenuated when transfected with the R270H variant. Further research is 
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needed to fully determine the functional implications of FFAR4 polymorphisms, but studies 
such as these are generating improved knowledge of how genotypic variation in nutrient 
receptors manifests in phenotypes of eating behaviour that may increase the risk of obesity. 
 
2.7.6 Fatty acid receptor FFAR1  
2.7.6.1 Oral FFAR1 
FFAR1 is present in lingual taste cells in mice34, yet it has been inconsistently reported 
in rat and human lingual epithelium32,122,124 and its presence in the human oral epithelium 
remains controversial. FFAR1 is activated by LCFA, and mice that lack FFAR1 possess 
diminished taste nerve responses to, and preference for, LCFA (i.e., linoleic acid), while 
responses to other taste stimuli (e.g., bitter, sweet, salty, and umami) remain intact34. 
Interestingly, six non-fatty acid agonists of FFAR1 (Rosiglitazone, Medica 16, Compound 
9.2, Compound 5, Compound 20, and Compound 10.14) are detected in sip-and-spit tests 
in humans and trigger a fat taste similar to linoleic acid; however, in 2-bottle preference 
tests in mice, these agonists were not sufficient to modify taste preference137. This 
indicates that FFAR1 activation generates a taste response, but may not be sufficient, alone, 
to modify taste preference; further human investigations are required to support this notion. 
 
2.7.6.2 Intestinal FFAR1 
 FFAR1 is highly expressed in pancreatic β-cells, and is also found in L- and K-cells of the 
proximal intestine in mice, where it co-localises with GLP-1 and GIP, respectively39. As 
such, FFAR1 can enhance glucose-stimulated insulin secretion (GSIS) via direct actions 
on the pancreas38, and indirectly via regulation of incretin hormone release from 
enteroendocrine cells39. Due to its tissue distribution and documented effects on fat-
mediated insulin release, FFAR1 is an attractive target for potential treatment of obesity 
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and T2D, with early reports suggesting that FFAR1 KO mice were resistant to numerous 
HFD-induced effects, including hyperinsulinaemia, hyperglycaemia, 
hypertriglyceridaemia, and hepatic steatosis42, and as such, that FFAR1 antagonists have 
the potential to prevent and treat obesity and T2D. Furthermore, linoleic acid-induced CCK 
secretion is abolished in pure populations of I-cells isolated from FFAR1 KO mice40, which 
is an effect not previously seen in studies using STC-1 cell lines27 and demonstrates that 
FFAR1 mediates LCFA-induced CCK secretion in response to dietary fat. However, later 
studies using the same HFD failed to show any protective effects in FFAR1 KO mice, and 
HFD exposure caused obesity, insulin resistance, and fatty liver41. Moreover, chronic 
over-expression of FFAR1 in β-cells of transgenic mice led to lipotoxicity and diabetes 
due to pancreatic dysfunction42. 
 
Further research is required to determine the extent to which FFAR1 mediates fat-induced 
effects on satiety and glycaemic control. For example, DIO and DIO-R rats subjected to a 
10-week HFD demonstrated upregulated FFAR1 transcript and protein expression upon 
intragastric nutrient exposure, concurrent with decreased CCK, GLP-1, and PYY peptide 
expression36. The reasons behind this differential response to fatty acids at the GPR and 
gut peptide level during obesity remain unclear, and the debate continues as to whether 
FFAR1 agonists or antagonists would constitute the most appropriate therapeutic strategy. 
 
2.7.6.3 FFAR1 polymorphisms 
While mutations in FFAR1 have been identified, and include an Arg211His 
polymorphism, or the rare mutation variant Asp175Asn, there is little agreement on their 
functional implications82-84 (see Table 2.2). One study found no significant relationship 
between Arg211His polymorphisms and insulin secretion or T2D risk82, while another 
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reported that this polymorphism explained variations in serum insulin levels in Japanese 
men83. A study into a newly identified polymorphism, Gly180Ser, identified impaired 
intracellular calcium increase as the basis for inadequate β-cell sensing of dietary lipids as 
an insulin secretory stimulus84. While further research is needed to uncover the 
contribution of genetic differences in FFAR1 to energy intake and glycaemic control, it 
remains a therapeutic target of interest, due to its potential to control the incretin axis in 
patients with T2D. 
 
2.7.7 Fatty acid receptor GPR119 
The receptor GPR119 was originally localised to pancreatic islets, where it is highly 
expressed and modulates GSIS47. Importantly, however, GPR119 is also localised to 
L-cells of the small intestine, where it mediates glucose-independent GLP-1 secretion138. 
The restricted localisation of GPR119 makes it an attractive therapeutic target for both 
obesity and T2D, due to its potential to promote both euglycaemia, and satiety. For 
example, ileal perfusion of OEA, a naturally occurring fatty acid amide and an endogenous 
ligand for GPR11948, induces GLP-1 secretion46. GPR119 is also expressed in GLUTag 
cells, human NCI-H716, and rat primary intestinal cell lines; in the last, OEA has been 
shown to increase GLP-1 secretion via GPR119 activation46. 
 
However, OEA-dependent suppression of food intake is intact in mice that lack GPR119, 
indicating that other pathways are involved in mediating the hypophagic effects of OEA47. 
Oral administration of the GPR119 agonist AR231453 in mice stimulates GLP-1 release 
and improves glucose tolerance, an effect abolished by blockade of GLP-1 receptor 
signalling50. Combined administration of AR231453 plus sitagliptin, an inhibitor of the 
GLP-1 breakdown enzyme dipeptidyl peptidase-4, enhanced the effect of AR231453, 
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whereas the presence of sitagliptin had no such effect in GPR119 KO mice50. Despite these 
findings in mice, the extent to which GPR119 agonists modulate GLP-1 release in humans, 
and their subsequent effects on energy intake and glycaemia, is unclear, and the few 
completed Phase II trials have not provided grounds for optimism (see review by Kang139). 
 
2.7.8 Fatty acid sensor CD36 
2.7.8.1 Oral CD36 
CD36 is a receptor-like glycoprotein that binds saturated and unsaturated LCFAs (carbon 
chain ≥ 16) in foliate and CV papillae in the rodent and human oral epithelium. CD36 is 
absent from non-gustatory oral tissue, highlighting its taste-specific function3,51. CD36 also 
mediates fat preference; this was demonstrated through a loss of preference for fatty acids 
(linoleic acid) in CD36 KO mice compared to their WT counterparts, while sensitivity to 
other taste modalities remained functional3. 
 
2.7.8.2 Intestinal CD36 and fatty acid transport 
CD36 is present in the BBM of enterocytes of the proximal intestine, the primary site of fat 
absorption, suggesting a role for CD36 in fatty acid uptake55. Functional evidence for such 
a role comes from KO mice, and studies of polymorphisms in rodents and humans. CD36 
KO mice fed a HFD for 6 weeks, and equipped with lymph duct fistulae, had impaired lipid 
secretion into the mesenteric lymph in the proximal small intestine, reflecting an impaired 
ability to uptake fatty acid into enterocytes, synthesise TAG, and form lipoproteins in the 
absence of CD3652. 
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Research into the intracellular signalling mechanisms linking fat ingestion to satiety have 
shown that activation of CD36 by LCFA induces the production and/or mobilisation of OEA, 
an effect that is abolished in CD36 and PPAR-α KO mice56. CD36 may also influence the 
CCK-mediated effects on satiety, with CD36 KO mice also demonstrating a significant 
reduction in CCK secretion in response to intragastric lipid infusion compared to WT 
mice140. A similar reduction in CCK secretion is also seen in response to fatty acids in STC-1 
cells generated to stably express a mutated form of human CD36 (CD36K/A), which impairs 
CD36-mediated signalling to intracellular calcium but has normal FFA uptake ability140. In 
CD36-deficient humans, abnormal plasma lipid profiles are also observed, including higher 
postprandial hypertriglyceridaemia, which may also imply a defective clearance of dietary 
TAGs135. However, more research is required into the specific mechanisms involved. 
Therefore, in addition to a transporter role, CD36 may also influence the satiety effects of 
fat ingestion, a pathway potentially mediated by OEA. 
 
2.7.8.3 CD36 polymorphisms  
The SNP rs1761667 is a common variant in the CD36 gene leading to reduced CD36 
expression, and is associated with human obesity. Obese subjects homozygous for the 
A-allele, which is associated with lower CD36 expression, have lower sensitivity (i.e., higher 
detection thresholds) to oleic acid and triolein emulsions85. Several SNPs of CD36 are also 
associated with measures of whole-body adiposity, including BMI and waist circumference, 
in European populations87,88 (Table 2.2). Importantly, many of the numerous genetic 
variants of CD36 do not confer changes to the protein. While it is important to clarify which 
polymorphisms affect protein availability and/or function, identifying relationships between 
the non-functional variants in the gene with phenotypes of eating behaviour will be of value 
in investigating markers of chronic disease risk141. 
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2.7.8.4 CD36 and high-fat diet exposure 
Studies in rodents have established links between CD36 expression and susceptibility to 
obesity. For example, data in mice show that CV papillae protein levels of CD36 reduce 
significantly 1 hour after re-feeding, and are followed by a progressive return to levels 
observed during fasting, with an inverse correlation between CD36 protein and food 
intake142. Conversely, exposure to a 3-day HFD upregulates CD36 expression in rats54 and 
may explain the increased capacity to absorb fat in the small intestine in obesity143. 
 
Importantly, there are differences in the responsiveness of CD36 receptors to fat exposure 
that align with reported differences in CD36 expression among rat strains53,144. These 
findings add support to a role of intrinsic variation in CD36 in response to fatty acid 
exposure, leading to overconsumption in the obese. For example, CD36 expression on the 
tongue and duodenum was assessed at 2 time points to assess acute response (3-day HFD) 
and adaptive response (14-day HFD) in rat strains either resistant to (S5B) or prone to obesity 
(OM). Basal levels of oral CD36 were not significantly different between strains, however 
consumption of a HFD induced significant strain-specific changes in CD36144. Oral CD36 
expression was significantly increased by HFD consumption in OM rats only, with a greater 
consumption of HFD compared to S5B at both time points, linking increased CD36 with 
hyperphagia in these rats. Duodenal expression was higher at baseline in S5B rats; however, 
duodenal CD36 expression only increased following the 14-day HFD, whereas OM rats 
increased duodenal CD36 expression and persistently overconsumed fat at both time points, 
indicating an increased absorptive capacity for FFAs but a deficiency in satiety signalling in 
this strain144. This may indicate that S5B rats are more resistant to HFD challenges, with 
CD36 receptors able to generate sufficient responses to FFAs to promote adequate feelings 
of satiety. Therefore, increased expression and availability of CD36 may not necessarily 
confer differences in function/sensitivity. Studies such as these highlight that CD36 
Literature Review  Chapter 2 
 
36 
signalling can be modulated by chronic fatty acid exposure, with implications for orosensory 
perception of dietary fats, satiety signalling, and activation of reward pathways, factors 
which may promote  overconsumption, particularly in obesity.  
 
2.7.8.5 CD36 and the gut microbiota 
Observations of distinct differences in the gut microbiome in genetically obese rodents and 
humans have piqued the interest of researchers145. Very little is known about the interaction 
and significance of the microbiome to nutrient sensing, although it has recently been shown 
that germ-free mice, lacking microbiota, are significantly leaner on a standard-chow diet 
compared to normal animals, despite having a higher energy intake146. Moreover, germ-free 
mice are completely resistant to HFD-induced obesity147. Interestingly, although germ-free 
mice demonstrate an increased preference for caloric intake from fats relative to normal 
mice, this is associated with increased lingual levels of CD36, yet a marked decrease in 
intestinal expression of both FFAR1 and FFAR4, as well as CCK, PYY, and GLP-1148. The 
potential role of gut microbiota in metabolism, energy intake, and body weight, highlights 
the complexity of investigations into taste receptor function in health and disease. The 
significance of an altered microbiome in metabolic diseases represents a novel area of gut 
research, although more investigation is required to ascertain how microbiota communicates 
with the gut to regulate intestinal nutrient sensing. 
 
2.8 Conclusion 
The gut plays a critical role in the control of appetite, energy intake, and glycaemia. The 
exact mechanisms that mediate gut hormone responses to nutrient intake are not established, 
but sufficient evidence now indicates that oral and intestinal taste receptors can determine 
the sensitivity to, preference for, and, ultimately, the metabolic response to ingested 
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nutrients. Studies of genetic modifications within these sensing pathways (e.g., human 
polymorphisms, genetically prone obese animal models) are now revealing their functional 
role in both health and metabolic diseases. The role of STRs in sweet taste sensing is well 
established in rodents and emerging in humans, with links to glucose absorption highlighting 
the importance of this luminal sensor in the control of postprandial glycaemia. This is 
observed through the augmentation of glucose absorption by intestinal STRs during 
hyperglycaemia in T2D patients, as well as evidence that STR blockade dose-dependently 
reduces glucose-stimulated incretin hormone release. Whether or not direct blockade of 
STRs is effective in controlling glycaemia in human T2D remains an exciting new area of 
investigation with the capacity for widespread benefits in the clinical setting. 
 
Given the high fat intake associated with modern diets, it is now important to increase 
understanding of how the function of FFA receptors may change in response to dietary cues. 
Candidate receptors such as GPR119, while initially a promising target to modulate 
glycaemia through pancreatic and intestinal incretin secretion, has proven to be less 
successful in the clinical setting. Similarly, there is controversy in the literature regarding 
the potential for therapeutic development targeting FFAR1, since it is unclear whether 
agonism or antagonism of this receptor would be more beneficial. Finally, FFAR4 has 
emerged as a leading receptor target with consistent functional impact, which is particularly 
evident in KO models via effects on GLP-1 secretion. The critical next step in taste receptor 
research is to translate the findings that link receptor activation, hormone release, and altered 
GI function to modifications in eating behaviour and glycaemic control in animals to positive 
outcomes in patients with obesity and T2D. If this is achieved, these receptors will provide 
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Background and aims: FFAs and their derivatives are detected by GPRs on 
enteroendocrine cells, with specific transporters on enterocytes. It is unknown whether acute 
fat exposure affects FFA sensors/transporters, and whether this relates to hormone secretion 
and habitual fat intake.  
 
Methods: We studied 20 healthy participants (10M, 10F; BMI: 22 ± 1 kg/m2; age: 28 ± 2 
years), after an overnight fast, on 2 separate days. On the first day, duodenal biopsies were 
collected endoscopically before, and after, a 30-min ID infusion of 10% Intralipid®, and 
relative transcript expression of FFAR1, FFAR4, GPR119 and the FFA transporter CD36 
was quantified from biopsies. On the second day, ID Intralipid® was infused for 120-min, 
and plasma concentrations of CCK and GLP-1 evaluated. Habitual dietary intake was 
assessed using FFQs.  
 
Results: ID Intralipid® increased expression of GPR119, but not FFAR1, FFAR4 and CD36, 
and stimulated CCK and GLP-1 secretion. Habitual PUFA consumption was negatively 
associated with basal GPR119 expression. 
 
Conclusions: GPR119 is an early transcriptional responder to duodenal lipid in lean humans, 
although this response appeared reduced in individuals with high PUFA intake. These 
observations may have implications for downstream regulation of gut hormone secretion and 
appetite. This study was registered as a clinical trial with the Australia and New Zealand 
Clinical Trial Registry (Trial number: ACTRN12612000376842). 
 




Dietary TAGs stimulate upper GI motor activity and hormone secretion, and suppress 
appetite and energy intake in humans149. The liberation of FFAs is critical for the sensing of 
fat in the GI tract, since fat-induced responses are attenuated when TAG digestion is blocked 
by lipase inhibitors150. FFAs with a carbon chain length ≥ 12, in particular, are potent stimuli 
of GI activity and interact with FFAR4 and FFAR1 on enteroendocrine cells within the small 
intestine28,40. Importantly, these fat sensors play a role in mediating GI hormone secretion in 
rodents, but their expression and function is poorly characterised in humans.  
 
FFAR4 and FFAR1 are present on enteroendocrine cells that release the gut hormones, CCK 
(from small intestinal I-cells) and GLP-1 (from small intestinal L-cells). Attenuated 
fat-induced hormone release from these cells has been demonstrated using RNA 
interference28 or genetic KO40 of these receptors. GPR119 is also present on L-cells, but, in 
contrast to FFARs, is activated by 2-monoacylglycerols and fatty acid derivatives, including 
the lipid messenger, OEA46,151. A functional role for GPR119 in fat-induced hormone 
signalling is evidenced by RNA inhibition of GPR119 in mouse GLUTag cells, which leads 
to reduced OEA-induced GLP-1 secretion46. The absorption of dietary LCFAs by 
enterocytes is mediated by the brush border transporter, CD36152. This transporter is a critical 
determinant of OEA mobilisation, which is markedly attenuated in CD36 KO mice56. 
 
Human obesity appears to be associated with reduced oral and GI sensitivity to fat, reflected 
in reduced fat-induced suppression of energy intake and GI hormone release127. Positive 
associations between duodenal expression of FFAR4 and CD36 with BMI have been 
reported, along with reduced numbers of enteroendocrine I- and L-cells153. Importantly, 
these fat sensors in the small intestine represent a unique system which may be dysregulated 
in obesity. However, whether these receptors respond to an acute fat stimulus, and whether 
Duodenal fat sensors in healthy humans  Chapter 3 
 
42 
this is associated with subsequent gut hormone secretion, has not been assessed in humans. 
Investigating the influence of habitual fat intake on the expression of fat sensors in health is 
an important first step to determining their role in settings of high-fat consumption and 
obesity.  
 
The aims of this study were, therefore, to investigate whether acute ID lipid infusion would 
alter expression of FFAR1, FFAR4, GPR119 and CD36 in the duodenum of lean, healthy 
participants, and whether this expression would be associated with fat-stimulated CCK and 
GLP-1 secretion, and related to habitual fat intake. We hypothesised that 1) acute ID lipid 
infusion would alter expression of these fat sensors, 2) these changes would be associated 
with fat-induced CCK and GLP-1 release, and 3) habitual fat intake would relate to basal 
FFAR1, FFAR4, GPR119 and CD36 expression. 
 
3.3 Materials and methods 
3.3.1 Participants 
Twenty healthy volunteers (10M, 10F; 28 ± 2 years; BMI: 22 ± 1 kg.m2) participated in the 
study. Participants were recruited through an existing departmental database, newspaper 
advertisement, and flyers at local universities and hospitals. All participants were of stable 
weight for at least 3 months prior to inclusion in the study and were unrestrained eaters (score 
≤ 12 in the eating restraint section (Factor 1) of the Three-Factor Eating Questionnaire 
(TFEQ)154). Participants reported no GI symptoms, had no prior GI surgery, did not take 
medications or supplements known to affect GI motility or appetite, consumed ≤ 20 g of 
alcohol per week, were non-smokers, and did not regularly consume fish oil supplements. 
The study protocol was approved by the Royal Adelaide Hospital Research Ethics 
Duodenal fat sensors in healthy humans  Chapter 3 
 
43 
Committee and carried out in accordance with the Declaration of Helsinki as revised in 2000. 
Written informed consent was obtained from each participant prior to inclusion in the study.  
 
3.3.2 Study design and protocols  
3.3.2.1 Part A: Endoscopy and collection of duodenal mucosal biopsies 
Participants attended the Department of Gastroenterology and Hepatology, Royal Adelaide 
Hospital, at 0830 h following a standardised evening meal (400g beef lasagne, energy 
content: 2470 kJ; fat, 20g; protein, 20g; carbohydrate 80g; McCain’s Foods, Australia) and 
an overnight fast of 12 h from solids and 10 h from liquids. Anaesthetic spray 
(Co-Phenylcaine Forte Nasal Spray, ENT Technologies, Australia) was then administered 
into the nasal cavity and pharynx, and a small diameter video endoscope (external diameter: 
5.3 mm, GIF-XP160, Olympus), lubricated with lignocaine gel (Orion Laboratories, 
Australia), was passed through the nose into the second part of the duodenum. Once 
positioned (t = 0 min), 2 duodenal biopsies were collected using standard endoscopic biopsy 
forceps and placed immediately in Allprotect® Tissue Reagent (Qiagen, Australia). 
Following this, an ID infusion of 10% Intralipid® (Fresenius Kabi AB, Sweden; 2 kcal/min) 
commenced via the endoscope infusion channel for 30 min. This design was based on our 
previous endoscopic studies combining nutrient infusion and biopsy collection, and 
establishing that expression of small intestinal glucose sensors was modulated within that 
time (i.e., 30 min) in humans1. At the conclusion of the ID infusion (t = 30 min), two 
additional biopsies were collected, and the endoscope removed. Participants were provided 
with a meal and discharge instructions and then permitted to leave the hospital. 
 
3.3.2.2 Part B: Intraduodenal lipid infusion  
Participants attended the Discipline of Medicine at 0830 h following a standardised evening 
meal and overnight fast, as described above. Anaesthetic spray and gel was administered 
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into the nasal cavity (as above) prior to insertion of a small-diameter (3.5 mm) catheter 
(Dentsleeve International, Mui Scientific), which was allowed to pass via peristalsis through 
the pylorus into the second part of the duodenum. Accurate positioning of the catheter across 
the pylorus was achieved by monitoring the transmucosal potential difference using a Red 
Dot monitoring electrode (3M Healthcare) placed on the forearm as a reference155. Once 
positioned, an IV cannula was inserted into a forearm vein, and a baseline blood sample (10 
ml) was collected (t = 0 min). ID infusion of 10% Intralipid® then commenced at a rate of 2 
kcal/min for 120 min (t = 0 - 120 min), during which blood samples were collected every 15 
min and placed in ice-chilled EDTA-treated tubes. Plasma was separated by centrifugation 
for 15 min at -4°C within 15 min of collection. Our study design purposefully omitted a 
control (saline) arm, as we have shown previously, under the same study conditions that ID 
infusion does not affect GI hormone secretion133,150,156,157. Mindful of the burden on 
participants, we considered that repeating this was unjustified. 
 
3.4 Measurements 
3.4.1 RNA extraction 
Frozen duodenal biopsies were disrupted using a bead-based tissue homogeniser 
(TissueLyser LT, Qiagen) and homogenised through Qiashredder columns (Qiagen). Total 
cellular RNA was isolated using the PureLinkTM MicroKit (Invitrogen, Thermo Fisher 
Scientific), which included an on-column DNase digestion, as per manufacturer’s 
instructions. RNA quantity was determined using a NanodropTM Lite Spectrophotometer 
(Thermo Fisher Scientific) and purity assessed using A260/A280 ratio.  
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3.4.2 Quantification of gene expression by relative RT-PCR 
Real-time RT-PCR was performed using the 7500 fast Real-Time PCR system (Applied 
Biosystems, Thermo Fisher Scientific). Taqman® primers (Life Technologies, Thermo 
Fisher Scientific) were used to determine the expression of FFAR1 (Hs03045166_s1, 
product# 4453320), FFAR4 (Hs00699184_m1, product# 4453320), GPR119 
(Hs02825719_s1, product# 4453320) and CD36 (Hs01567185_m1, product# 4448892) 
relative to expression of the housekeeper β2M (HS00984230_m1, product# 4331182). All 
targets were assessed in triplicate according to manufacturer’s instructions. 
 
3.4.3 Gut hormones 
Plasma CCK. Plasma CCK-8 concentrations (pmol/L) were measured by radioimmunoassay 
using a protocol adapted from Santangelo and colleagues158. Samples were extracted in 66% 
ethanol; extracts were dried down and resuspended in assay buffer (50 mM phosphate, 10 
mM EDTA, 2 g/L gelatin, pH 7.4). Standards were prepared using synthetic sulphated 
CCK-8 (Sigma Chemical) with antibody (C2581, Lot 041K4838, Sigma Chemical) added at 
a working dilution of 1:17,500. Sulphated CCK-8 125I-labeled with Bolton and Hunter 
reagent (Perkin Elmer, USA) was used as tracer. Incubation was for 7 days at 4˚C. The 
antibody-bound fraction was separated by the addition of dextran-coated charcoal containing 
gelatin (0.015 g gelatin, 0.09 g dextran, 0.15 g charcoal in 30 ml assay buffer) and the 
radioactivity determined in the supernatants following centrifugation. The antibody binds all 
CCK peptides containing sulphated tyrosine residue in position 7, shows a 15% 
cross-reactivity with non-sulphated CCK-8, ≤ 2% cross-reactivity with human gastrin I, 
0.1% with CCK (30-33) and 1% with human Big Gastrin, and does not bind structurally 
unrelated peptides. Intra-assay CV was 5.2% and inter-assay CV was 15.4%. The detection 
limit was 1 pmol/L. 
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Plasma GLP-1. Plasma total GLP-1 concentrations (pg/mL) were analysed using a multiplex 
assay (Milliplex® MAP Human Metabolic Hormone Magnetic Bead Panel, HMHEMAG-34K) 
using the Bio-plex® MAGPIXTM Multiplex Reader (Luminex®, Millipore Corporation) and 
xPONENT® software (Luminex®, Millipore Corporation, version 4.2) according to 
manufacturer’s instructions. There was negligible antibody cross-reactivity. Intra-assay CV 
was ≤ 10%, and inter-assay CV was ≤ 15%. The detection limit was 2.5 pg/mL.  
 
3.4.4 Habitual dietary intake 
A FFQ was completed by each participant to assess their average daily energy and fat intakes 
over the previous 12 months (DQES v2; Cancer Council Victoria, Carlton, Victoria, 
Australia159). This questionnaire has been validated for use in Australian adults160. 
 
3.4.5 Data and statistical analyses 
Sample size was based on power functions derived from our a priori data153 using 
within-subjects contrasts with P ≤  0.05 and statistical power (1-β) = 0.8. Statistical analysis 
was performed using SPSS® software (SPSS Inc, IBM®, version 20), and all graphs were 
generated using GraphPad Prism 6 (GraphPad Software Inc). One-way analysis of variance 
(ANOVA) with post-hoc Bonferroni testing was used to compare basal expression of all 
receptor targets. Paired samples t-tests were used to compare post-infusion (t = 30 min) 
expression with baseline (t = 0 min) for each of FFAR1, FFAR4, GPR119 and CD36. 
Relationships between receptor expression and habitual energy and fat intake were 
determined by correlation, with Pearson’s r values presented.  Paired samples t-tests were 
also used to compare gut hormone stimulation at t = 120 min with baseline concentrations  
(t = 0 min). Blood samples were collected on the longer infusion day for logistical reasons, 
as our research has shown that plasma CCK161 and GLP-1162 concentrations are comparable 
across multiple, identical study day visits. Hormone data were expressed as AUCs 
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(calculated using the trapezoidal rule from t = 0 min to 120 min). This AUC value (pmol.L 
min-1 or pg.mL min-1) was divided by the time of last measurement to obtain a final weighted 
average (AUC, pmol/L or pg/mL) to account for occasions (in n = 2 participants) when 
samples could not be collected (e.g., bathroom breaks). Relationships between receptor 
expression at t = 0 min and t = 30 min with plasma hormone AUC, were determined by 
correlation, Pearson’s r values presented. Data are expressed as means ± standard error of 
the mean (SEM), with statistical significance accepted at P ≤ 0.05. 
 
3.5 Results 
Endoscopic and infusion procedures were well tolerated, and biopsies were successfully 
collected from all 20 participants.  
 
3.5.1 Expression of fat sensors in the proximal human duodenum following 
acute ID lipid exposure 
Expression of FFAR1, FFAR4, GPR119 and CD36 was detected in all duodenal biopsies at 
baseline, with relative abundance of CD36>>FFAR1>FFAR4>GPR119 (all P ≤ 0.05). ID 
lipid infusion increased duodenal expression of GPR119 (P ≤ 0.05), while other transcripts 
were unchanged. β2M was stably expressed in all biopsies and unchanged by the 











Figure 3.1: Relative transcript expression of FFAR1 (A), FFAR4 (B), GPR119 (C), and CD36 (D) in human duodenal biopsies at baseline (T0) and 
following 30 min ID Intralipid® infusion (T30) (2 kcal/min). Expression of A) FFAR1, B) FFAR4 and D) CD36 mRNA expression was unchanged by ID 
lipid infusion. C) GPR119 mRNA expression increased at t = 30 min (inset: optimised axes, *P ≤ 0.05) following ID lipid infusion. Data are expressed as 
mean ± SEM, n = 20. 
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3.5.2 Gut hormones 
ID lipid stimulated CCK release (P ≤ 0.05, Figure 3.2). The time to maximum concentration 
(TMax, group median), maximum concentration (CMax, group mean) and total AUC are 
detailed in Table 3.1. There was no correlation between FFAR1, FFAR4, CD36 and 
GPR119 expression at baseline, or following ID lipid, and CCK AUC.  
 
ID lipid also stimulated release of GLP-1 (P ≤ 0.05, Figure 3.2). The TMax, CMax and total 
AUC are indicated in Table 3.1. There was no correlation between FFAR1, FFAR4, GPR119 
and CD36 expression at baseline, or following ID lipid, and GLP-1 AUC. 
 
3.5.3 Relationship between habitual fat intake and duodenal expression of 
FFARs and CD36 
Habitual dietary intake assessed from FFQs is summarized in Table 3.2. Three participants 
had incomplete questionnaires, which were rejected by the automated analysis. There were 
no relationships between baseline, or post-lipid duodenal expression, of FFAR1, FFAR4, 
GPR119 or CD36 with habitual energy, total fat, saturated fat, monounsaturated fat, protein, 
or carbohydrate intakes. Habitual PUFA consumption (13 ± 1 g/day) was negatively 
correlated with basal duodenal GPR119 expression (r = -0.5, P ≤ 0.05, Figure 3.3).  
a 





Figure 3.2: Plasma CCK (A) and GLP-1 (B) concentrations during 120 min ID 
Intralipid® infusion (2 kcal/min). Plasma CCK and GLP-1 were both increased by ID lipid 














Figure 3.3: Relationship between habitual consumption of PUFAs (g/day) and 
duodenal mRNA expression of GPR119.  Habitual consumption of PUFA was negatively 
correlated to basal expression of GPR119 (r = -0.5, n = 17, P ≤ 0.05).  
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Table 3.1: Plasma gastrointestinal hormone concentrations in healthy, lean humans 
during 120-min ID Intralipid® infusion (2 kcal/min). 
Hormone Tmax (min) Cmax AUC 
CCK (pmol/L) 
(n=19) 
15 7.9 ±  0.6 7.5 ± 0.6 
GLP-1 (pg/mL) 
(n=17) 
90 168 ± 21 105 ± 10 
Data are mean ± SEM. AUC: Area under the curve; CCK: Cholecystokinin; Cmax; 
maximum concentration; GLP-1: glucagon-like peptide-1; Tmax: time to maximum 
concentration 
 
Table 3.2: Average daily energy and macronutrient intake assessed over the previous 
12 months  
 
Mean ± SEM 
Energy intake, kJ/day 9757 ± 785 
Total fat, g/day 99 ± 9 
Saturated fat, g/day 41 ± 4 
Polyunsaturated fat, g/day 13 ± 1 
Monounsaturated fat, g/day 36 ± 4 
Protein, g/day 121 ± 13 
Carbohydrates, g/day 241 ± 17 
Sugars, g/day 103 ± 10 
Starch g/day 137 ± 10 
Fiber, g/day 27 ± 3 
  




This study has evaluated the expression of the fat sensors, FFAR1, FFAR4, GPR119, and 
the sensor/transporter, CD36, in the human duodenum, and the effects of acute ID lipid 
infusion. We showed expression of these targets in the duodenum of healthy participants, 
with relative abundance mirroring our earlier findings153. CD36 was the most abundant 
transcript expressed in the duodenum, consistent with its known localisation to the BBM of 
enterocytes and suggested FFA transport capabilities153. We further demonstrated that an 
acute, meal-relevant fat stimulus, known to trigger acute GI responses (as evidenced by gut 
hormone secretion), increased expression of GPR119, but not FFAR1, FFAR4 or CD36, in 
the duodenum of healthy participants. In addition, GPR119 expression was negatively 
correlated with habitual PUFA intake, supporting an ability of long-term dietary patterns to 
influence the availability of this sensor. These results are novel and bridge a gap in our 
understanding of how transcriptional control of these FFA-sensing GPRs is regulated in an 
acute in vivo setting. 
 
Lipid-induced increases in GPR119 expression in our study, if linked to increased 
availability of the apical receptor, or its signalling, would support a capacity to respond to 
the ongoing presence of luminal fat. This, in turn, may augment secretion of gut hormones 
and/or increase satiety signalling. Although we did not detect significant associations 
between GPR119 and hormone secretion, this may have been due to a type 2 error owing to 
the relatively small sample size. Further, while the magnitude of the change in GPR119 
expression was modest,  previous work utilising RNA interference of GPR119 has 
demonstrated that even modest knockdown of GPR119 transcript (23%) in mGLUTag cells 
was sufficient to block the rise in cAMP in response to a GPR119-specific stimulus, and also 
resulted in a 45% reduction in GLP-1 secretion46. While the mechanisms linking luminal 
sensing and hormone secretion are largely unknown and cannot be derived from the current 
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data, there is extensive evidence supporting a role of GPR119 in mediating 
glucose-independent incretin secretion from enteroendocrine cells50, and growing evidence 
for a role in satiation46.  
 
GPR119 is tuned to detect the oleic acid derivative, OEA, a potent trigger for GLP-1 
secretion in human and rodent cell lines46. OEA and small molecule agonists of GPR119 are 
capable of suppressing food intake in animals, the former by prolonging latency between 
meals163. However, the hypophagic capacity of OEA is not established in humans, further 
complicated by the ability for OEA to signal through multiple mechanisms, for example via 
PPAR-α, a pathway implicated in the absorption, storage and utilisation of dietary fat56,163. 
Indeed, mice lacking CD36 (required for fat-induced OEA production in enterocytes) or 
PPARα show attenuated fat-induced satiety56, suggesting that the appetite-suppressant 
effects of OEA may be GPR119- and CD36-dependent.  
 
GPR119-mediated satiation may also be linked to GLP-1 release and subsequent activation 
of GLP-1 receptors on mucosal vagal afferents. As vagal afferent endings do not directly 
interact with luminal content, it is feasible that GPR119 may link luminal fats to secretion 
of hormones, such as GLP-1. While there is currently no direct evidence in humans of a 
functional role for GPR119 in energy intake regulation,  ID infusion of the putative GPR119 
ligand, 2-oleylgylcerol, in humans increases plasma GLP-1 and GIP151, and the GLP-1 
antagonist, exendin(9-39), attenuates the beneficial glucoregulatory effects of the GPR119 
agonist, AR23145, in mice50. Therefore, a stimulus known to enhance incretin secretions in 
vivo also activates GPR119 in vitro, implicating GPR119 in this process. Our data show that 
acute fat exposure is not only sufficient to elicit a hormone response, but also triggers 
transcriptional regulation of GPR119. Together with previous work, our findings add support 
to the view that GPR119 activation may be linked to gut hormone secretion in humans.  
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We acknowledge that proteomics will be a critical step in accurately linking transcript 
changes seen in GPR119 to luminal receptor activity and intracellular/downstream signalling 
events. This remains a challenge for GPR119, as commercially available antibodies suitable 
for Western blotting for G-proteins are often found to be non-specific for the same target 
(for review see164). In addition, in-group anti-sera have also been shown to produce 
inconsistent immunolocalisation165,166. Nonetheless, transcript data here justify further 
proteomic investigations. GPR internalisation in the face of ongoing stimulus results in a 
loss of signalling fidelity, with evidence from cell-based assays revealing that FFAR1, 
FFAR4 and GPR119 show dose- and time-dependent internalisation in response to 
endogenous and synthetic agonists28,167-169. However, a sustained cAMP elevation has been 
noted in GPR119-containing HEK293 cells chronically exposed to physiological doses of 
OEA, or the synthetic GPR119 agonist, AR231435170. While discussion of these 
discrepancies is beyond the scope of this work, it highlights the fact that GPCR 
desensitisation in fat sensor systems is not well understood. 
 
Our results provide support that basal GPR119 expression is driven, at least in part, by 
habitual PUFA consumption. While studies have not previously addressed the relationship 
between long-term habitual fat intake and GPR119 gene expression, chronic consumption 
of a HFD is associated with obesity, while consumption of PUFA is linked to lower levels 
of adiposity171. PUFAs (such as linoleic acid) are known to bind to PPARα to regulate 
various genes involved in fat metabolism172, and although GPRs are uncommon targets of 
PPARα action, it is conceivable that factors which act upon this nuclear receptor may 
regulate GPR119 expression. Recent studies have also shown that the type and amount of 
habitual fat intake is an important predictor of intestinal OEA production, and therein, 
potential GPR119 activation. For example, a 1-week diet high in monounsaturated fatty 
acids (MUFAs), PUFAs, saturated and unsaturated fats in rodents attenuated basal jejunal 
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levels of OEA173, while 1 week of diets high in MUFAs (olive oil) had no effect on basal 
OEA levels in the rat jejunum174. Accordingly, participants with higher habitual PUFA 
intake in our study may have a greater capacity for PPARα activation, and lower basal 
GPR119 expression. The reasons for such an effect remain elusive, but illustrate the potential 
for habitual fat intake to influence expression of genes relating to fat sensing. A limitation 
of our study is that the FFQ analysis did not have the specificity to reveal habitual intakes of 
different PUFAs. In addition, the questionnaire may not accurately account for participants’ 
acute fat intake immediately prior to the study. Prospective studies are warranted to 
investigate the effects of dietary composition on fat sensor expression. 
 
In summary, this study provides the first evidence of transcriptional upregulation of GPR119 
in the face of an acute ID fat stimulus within the human duodenum. Further investigations 
that extend the postprandial period may reveal changes in other targets. We also revealed 
associations between GPR119 and habitual PUFA intake, indicating that fat sensing systems 
can be influenced by dietary fat intake. Further studies also need to determine the molecular 
mechanisms by which GPR119 operates in humans, and the significance of its endogenous 
ligands, such as OEA, in paracrine signalling within the duodenal mucosa. Finally, whether 
acute changes in GPR119 in response to fat are maintained under metabolic challenges, such 
as a HFD or in obesity, in humans should be the subject of further research, to determine the 
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Background and Aims: The small intestinal FFA sensors, FFAR1, FFAR4, GPR119 and 
CD36, mediate the fat-induced release of GI hormones. We investigated whether expression 
of duodenal FFA sensors in humans was (i) altered by ID lipid infusion, (ii) disordered in 
overweight or obese individuals, (iii) related to lipid-induced GI hormone secretion or (iv) 
affected by habitual dietary patterns. 
 
Methods: Endoscopic duodenal biopsies were collected from 20 lean (BMI: 22 ± 1 kg.m2), 
18 overweight (BMI: 27 ± 1 kg.m2) and 19 obese (BMI: 35 ± 1 kg.m2) participants at 
baseline, and following a 30 min ID Intralipid® infusion (2 kcal/min); FFA sensor expression 
was quantified by RT-PCR. On a separate day, participants underwent ID Intralipid® 
infusion (2 kcal/min) for 120 min, to assess GI hormone responses. Habitual diet was 
evaluated using FFQs. 
 
Results: Baseline FFAR1 and FFAR4 expression were lower, and CD36 higher, in obese 
compared to lean participants. ID lipid increased GPR119 and FFAR1 expression equally 
across study groups, but did not alter FFAR4 or CD36 expression. Increased FFAR1 
expression correlated positively with GIP secretion (r = 0.3, P ≤ 0.05), while there was no 
relationship between habitual diet with the expression of FFA sensors. 
 
Conclusions: Obesity is associated with altered duodenal expression of FFAR1, FFAR4 and 
CD36, suggesting altered capacity for the sensing, absorption and metabolism, of dietary 
lipids. GPR119 and FFAR1 are early transcriptional responders to the presence of ID lipid, 
while FFAR1 may be an important trigger for lipid-induced GIP release in humans. This 
study was prospectively registered with the Australia and New Zealand Clinical Trial 
Registry (www.anzctr.org.au trial number: ACTRN12612000376842). 




Small intestinal sensing of FFAs potently triggers the release of GI hormones such as CCK 
and GLP-1, slows gastric emptying, and suppresses subsequent energy intake150. However, 
chronic consumption of a HFD promotes increased energy intake175 and is associated with 
the development of obesity. In animal studies, chronic HFD consumption markedly 
attenuates GI sensing of dietary fat, GI hormone secretion, and motility responses (reviewed 
in176,177), and is likely to be an important mechanism underlying increased energy intake. 
While studies investigating the influence of HFD consumption on GI fat sensing in humans 
are limited, we previously reported that obese humans with high habitual fat and energy 
intakes had reduced stimulation of pyloric motility and CCK in response to ID infusion of 
the FFA, oleic acid (C18:1), and a higher energy intake at a subsequent ad libitum meal, 
when compared with lean individuals127. Collectively, this indicates that small intestinal 
sensitivity to fat may be reduced in human obesity, contributing to dysregulated energy 
intake. However, the mechanisms underlying these changes in GI fat sensing are poorly 
understood. 
 
Rodent models and cell line studies have determined that the FFA sensors, FFAR1, FFAR4 
and GPR119, localised on enteroendocrine cells, and the putative FFA transporter, CD36, 
localised on enterocytes, detect the presence of dietary FFAs in the small intestine and trigger 
the release of GI hormones28,36,38-40,46,178. We demonstrated that fasting duodenal expression 
of CD36 and FFAR4 were increased, and GPR119 decreased, with increasing BMI153. 
Furthermore, a 30-min ID lipid infusion upregulated duodenal expression of GPR119 in 
healthy, lean individuals, with the magnitude of this response reduced in individuals with a 
high habitual consumption of PUFAs179. Therefore, the expression of GPR119 is likely to 
be modulated both acutely by small intestinal nutrient exposure, and chronically by habitual 
dietary patterns. Small intestinal changes in FFA sensor expression would be likely to impact 
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downstream signalling events linked to GI hormone secretion and energy intake, but this has 
not been investigated in humans.   
 
Therefore, the aims of the current study were to (i) evaluate the effects of acute ID lipid 
infusion on the duodenal expression of the FFA sensors, FFAR1, FFAR4, GPR119 and 
CD36, in healthy lean, overweight and obese participants, and (ii) determine relationships 
between expression of these sensors and habitual fat and energy intakes, BMI, GI hormone 
secretion and ad libitum energy intake.  
 
4.3 Materials and methods 
4.3.1 Participants 
20 lean (10M: 10F, age: 28 ± 2 years; BMI: 22 ± 0.5 kg.m2), 18 overweight (12M: 6F, age: 
32 ± 3 years; BMI: 27 ± 0.3 kg.m2) and 19 obese (12M: 7F, age: 30 ± 2 years; BMI: 35 ± 1 
kg.m2) volunteers were included in the study. Participants were weight-stable for at least 3 
months prior to enrolment and were unrestrained eaters154. Participants had no GI symptoms 
or previous GI surgery, did not take medications or supplements known to affect GI motility 
or appetite, consumed ≤ 20g of alcohol per week, were non-smokers, and did not take fish 
oil supplements. At the screening visits, their HbA1c and iron levels were within normal 
ranges (Table 4.1). The study protocol was approved by the Royal Adelaide Hospital 
Research Ethics Committee and carried out in accordance with the Declaration of Helsinki. 
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Table 4.1: Participant demographics at initial screening 
 Lean Overweight Obese P 
n 20 18 19  
Sex 10M : 10F 12M : 6F 12M : 7F NS 
Age (years) 28 ± 2 32 ± 3 30 ± 2 NS 
BMI (kg.m2) 22 ± 0.5 27 ± 0.3 35 ± 1 *#˄P ≤ 0.001 
HbA1c % 5.2 ± 0.1 5.2 ± 0.1 5.3 ± 0.1 NS 
Iron (μmol/L) 21 ± 2 22 ± 1 20 ± 2 NS 
Data are mean ± SEM. *Lean vs overweight; #Obese vs lean; ˄Obese vs overweight  
 
4.3.2 Study design and protocols 
4.3.2.1 Part A: Endoscopic collection of duodenal mucosal biopsies 
Participants attended the Gastrointestinal Investigation Unit at the Royal Adelaide Hospital, 
at 0830 h, following a standardized evening meal (400g lasagne, 2470 kJ; fat, 20g; protein, 
20g; carbohydrate, 80g; McCain Foods, Australia) and an overnight fast (12 hrs for solids, 
10 hrs for liquids). The protocol for endoscopic collection of mucosal biopsies has been 
previously described179. Briefly, duodenal biopsies were collected using standard biopsy 
forceps, and separate biopsies collected into Allprotect® Tissue Reagent (Qiagen, Australia) 
or archived at -20˚C. An ID infusion of 10% Intralipid® (Fresenius Kabi AB, Sweden; 2 
kcal/min; 109 ml/hr) was then commenced via the infusion channel of the endoscope and 
maintained for 30 min, with two additional biopsies collected at the conclusion of the ID 
infusion (t = 30 min). The duration of infusion was based on a previous study from our group 
showing changes in intestinal expression of sweet taste receptors within 10 min of a 30-min 
ID infusion of glucose in humans1.   
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4.3.2.2 Part B: GI hormone, appetite, and energy intake responses to ID lipid 
Participants arrived at 0830 h following a standardised evening meal and overnight fast, as 
described above. A small-diameter (3.5mm) catheter was positioned in the second part of 
the duodenum, and an IV cannula inserted into a forearm vein and a baseline blood sample 
collected (t = 0 min), as previously described179. ID infusion of 10% Intralipid® was then 
commenced at a rate of 2 kcal/min for 120 min (t = 0 - 120 min). Blood samples were 
collected in ice-chilled EDTA-treated tubes every 15 min and separated by centrifugation 
(15 min at 4°C), within 15 min of collection. Visual analogue scales (VAS) were completed 
every 15 min from t = 0 – 120 min. At t = 120 min participants received a standardized, cold, 
buffet-style meal as previously described161.  
 
4.4 Measurements 
4.4.1 RNA extraction 
Frozen duodenal biopsies were disrupted using a bead-based homogeniser (TissueLyser LT, 
Qiagen) and homogenised through Qiashredder columns (Qiagen). Total cellular RNA was 
isolated using the PureLinkTM MicroKit (Invitrogen, Thermo Fisher Scientific, Australia) 
with on-column DNase digestion, as per the manufacturer’s instructions. RNA quantity was 
determined using a NanodropTM Lite Spectrophotometer (Thermo Fisher Scientific) and 
purity assessed using A260/A280 ratio. 
 
4.4.2 Quantification of FFA sensor expression by relative RT-PCR 
Real-time RT-PCR was performed using a 7500 fast Real-Time PCR system (Applied 
Biosystems, Thermo Fisher Scientific). Taqman® primers (Life Technologies, Thermo 
Fisher Scientific) were used to determine the expression of FFAR1 (Hs03045166_s1, 
product# 4453320), FFAR4 (Hs00699184_m1, product# 4453320), GPR119 
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(Hs02825719_s1, product# 4453320) and CD36 (Hs01567185_m1, product# 4448892) 
relative to expression of the housekeeper gene β2M (HS00984230, product# 4331182). All 
targets were assessed in triplicate according to manufacturer’s instructions. 
 
4.4.3 Gut hormones 
4.4.3.1 Plasma CCK 
CCK-8 was measured by radioimmunoassay using a protocol adapted from Santangelo and 
colleagues158, as described previously179. 
 
4.4.3.2 Total GLP-1 and GIP, PYY, insulin and leptin 
Total GLP-1 and GIP, PYY, insulin and leptin were determined using a multiplex assay 
(Milliplex® MAP Human Metabolic Hormone Magnetic Bead Panel, HMHEMAG-34K, 
Millipore Corporation, USA) and analysed on a Bio-plex® MAGPIXTM Multiplex Reader 
(Luminex®, Millipore Corporation) using xPONENT® software (Luminex®, Millipore 
Corporation, version 4.2) according to the manufacturer’s instructions. There was negligible 
antibody cross-reactivity. Intra-assay CV was ≤ 10%, and inter-assay CV was ≤ 15% for all 
analytes. The detection limits were: GLP-1, 2.5 pg/mL; GIP, 0.6 pg/mL; PYY 28 pg/mL; 
insulin 87 pg/mL; and leptin, 41 pg/ml.   
 
4.4.4 Blood glucose 
Venous blood glucose (mmol/L) was measured at collection by the glucose oxidase method 
using a portable glucometer (Medisense Precision QID; Abbott Laboratories, USA).  
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4.4.5 Appetite perceptions, and ad-libitum buffet meal intakes 
VAS were used to determine perceptions of hunger, fullness, desire to eat, prospective 
consumption, nausea and bloating180.  
 
Energy intake (kJ), amount (g) and percentage energy from fat, carbohydrate and protein 
consumed at the buffet meal was analysed using commercial software (FoodWorks® 2009, 
Version 6, Xyris Software Pty Ltd). 
 
4.4.6 Habitual dietary intake 
Participants completed a FFQ to assess their average energy and macronutrient intake (fat, 
carbohydrate, protein) over the previous 12 months (DQES v2; Cancer Council Victoria, 
Carlton, Victoria, Australia159). This questionnaire has been specifically validated for use in 
Australian adults160. 
 
4.4.7 Data and statistical analyses 
Sample size was based on power functions derived from our a priori data153 using 
within-subject contrasts of P ≤ 0.05 and statistical power (1-β) = 0.8. Statistical analysis was 
performed using SPSS® software (SPSS Inc, IBM®, Version 20), in collaboration with a 
professional biostatistician. Expression levels of FFA sensors at t = 0 min and t = 30 min 
were normalised to levels of β2M using delta CT comparison (cycle threshold - target of 
interest cycle threshold)181. One-way ANOVA was used to compare baseline (t = 0 min) 
expression of FFAR1, FFAR4, GPR119 and CD36, with BMI group (i.e., lean, BMI: 18-24 
kg.m2; overweight, BMI: 25-29 kg.m2; or obese, BMI ≥ 30 kg.m2) as the factor. Two-way 
repeated measures ANOVA was used to compare changes in receptor expression from 
baseline (t = 0 min) to post-infusion (t = 30 min), with BMI group as a between-subjects 
factor. Post-hoc pairwise comparisons, corrected for multiple comparisons using the 
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Bonferroni method, were performed if ANOVAs were significant. Baseline plasma hormone 
and blood glucose concentrations, and VAS scores, were calculated from mean values 
obtained at t = -15 min and t = 0 min. Blood samples were collected only on the longer 
infusion day for logistical reasons. We have previously demonstrated that plasma CCK and 
GLP-1 responses to nutrient do not differ across multiple, identical study days within an 
individual161, 162. iAUCs for gut hormones, blood glucose, and VAS were calculated using 
the trapezoidal rule from t = 0 min to 120 min (pmol.L min-1 or pg.mL min-1), which was 
divided by the time of last measurement to obtain a final weighted average (iAUC, pmol/L 
or pg/mL) to account for occasions (in n = 8 participants) when samples could not be 
collected (e.g., during bathroom breaks). In occasional instances where the t = 15 min time 
point was below the detection limit of the assay (PYY, n = 5; insulin, n = 3, leptin n = 1), 
the minimum limit of detection was halved to obtain a baseline estimate for iAUC 
calculation. The maximum concentration of blood glucose and gut hormones (CMax), was 
calculated from t = 0 - 120 min. Associations between the transcript expression and BMI, 
plasma hormones, blood glucose, and acute and habitual dietary intakes were determined by 
Pearson’s correlations, with r values presented, with transcript expression expressed as 
change from baseline (Δ, t30 - t0) due to variability in individual transcript data. Data are 
expressed as mean ± SEM, with statistical significance accepted at P ≤ 0.05. 
 
4.5 Results 
Endoscopic procedures were well tolerated, and biopsies collected from 56 out of 57 
participants. One obese participant did not complete the endoscopy for reasons unrelated to 
the study. Eight participants did not complete the full 120-min infusion protocol due to 
nausea (2 lean, 4 overweight, 1 obese; duration of infusion ranging from t = 15 min to t = 90 
min) or catheter displacement (lean, n = 1); buffet meal intake was not measured in these 
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participants. Eight participants (3 lean, 4 overweight, 1 obese) had incomplete FFQ 
questionnaires, which were, therefore, rejected by the automated analysis.  
 
4.5.1 Habitual dietary intake 
Average daily energy and macronutrient intakes over the previous 12 months did not differ 
between the lean, overweight and obese groups (Table 4.2).  
 
4.5.2 Duodenal FFA sensor expression at baseline and following the 30-min 
ID lipid infusion 
FFAR1, FFAR4, GPR119 and CD36 expression was detected in all duodenal biopsies at 
baseline (i.e., during fasting), with relative abundance CD36 >> FFAR1 > FFAR4 > GPR119 
seen in all subject groups (Figure 4.1). Expression of the housekeeper gene, β2M, was stable 
in all biopsies across time points and groups. Baseline FFAR1 expression was 62% lower in 
the obese compared with lean (P ≤ 0.05), and 51% lower in the overweight (P = 0.054) 
compared with lean, with no difference between obese and overweight groups. Baseline 
FFAR4 expression was 62% lower in the obese compared with the lean group (P ≤ 0.05), 
with no differences between overweight and obese, or overweight and lean groups. Baseline 
GPR119 expression was not different between the groups. CD36 expression was higher in 
the obese compared with both the lean (242-fold, P ≤ 0.001), and overweight (202-fold, P ≤ 
0.001) groups, with no difference between lean and overweight (Figure 4.2). 
 
Within each group, FFAR1 expression increased after ID lipid when compared to baseline; 
by 1.4 ± 0.2-fold in the lean (P ≤ 0.05), by 1.6 ± 0.2-fold in the overweight (P ≤ 0.05), and 
by 1.7 ± 0.3-fold in the obese (P ≤ 0.05). GPR119 expression also increased from baseline 
after ID lipid; by 2.0 ± 0.3-fold in the lean (P ≤ 0.05), by 2.4 ± 0.7-fold in the overweight   
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(P ≤ 0.05), and by 2.0 ± 0.3-fold in the obese (P ≤ 0.05). There was no effect of ID lipid on 
expression of FFAR4 and CD36 in any group (Figure 4.2).  
 
Table 4.2: Daily energy and macronutrient intakes over the previous 12 months, and 
ad libitum consumption at a buffet meal following 120 min ID Intralipid® infusion  
(2 kcal/min). 
Habitual Lean Overweight Obese P 
Energy intake (kJ/day) 9757 ± 785 9820 ± 857 9320 ± 1476 NS 
Total fat (g/day) 99 ± 9 99 ± 10 101 ± 17 NS 
Saturated fat (g/day) 41 ± 4 41 ± 5 43 ± 8 NS 
Polyunsaturated fat (g/day) 13 ± 1 13 ± 2 13 ± 2 NS 
Monounsaturated fat (g/day) 36 ± 4 36 ± 4 37 ± 6 NS 
Protein (g/day) 121 ± 13 126 ± 13 114 ± 15 NS 
Carbohydrates (g/day) 241 ± 17 239 ± 20 219 ± 36 NS 
Sugars (g/day) 103 ± 10 92 ± 11 87 ± 14 NS 
Starch (g/day) 137 ± 10 146 ± 13 131 ± 22 NS 
Fiber (g/day) 27 ± 3 25 ± 2 21 ± 3 NS 
Buffet meal     
Energy intake (kJ) 4413 ± 434 4407 ± 443 4125 ± 383 NS 
Amount (g) 1001 ± 88 1062 ± 78 931 ± 89 NS 
Fat (g) 38 ± 4 36 ± 5 40 ± 4 NS 
Fat (%) 32 ± 1 29 ± 2^ 36 ± 2^ ^ ≤ 0.01 
Protein (g) 60 ±7 57 ±7 56 ± 6 NS 
Protein (%) 23 ± 1 22 ± 1 23 ± 1 NS 
Carbohydrate (g) 115 ± 11 123 ± 11 99 ± 10 NS 
Carbohydrate (%) 43 ± 2 48 ± 3^ 40 ± 2^ ^ ≤ 0.05 
^Obese vs overweight; Data are mean ± SEM; Habitual, lean, n = 17; overweight, n = 14; 
obese, n = 18; Buffet meal, lean, n = 17; overweight, n = 14; obese, n = 18. 
  




Figure 4.1: Baseline (fasting) duodenal expression of FFAR1, FFAR4, GPR119 and 
CD36 in lean, overweight and obese humans. A) FFAR1 and B) FFAR4 expression was 
lower at baseline in obese compared to lean subjects (#P ≤ 0.05), but did not differ between 
lean and overweight participants. There were no differences in expression of C) GPR119 
between study groups, while D) CD36 expression was higher in obese compared to both lean 
and overweight participants (#˄P ≤ 0.001). Data are mean ± SEM. Lean (L, n = 20), 
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Figure 4.2: Intralipid®-induced changes in duodenal expression of FFAR1, FFAR4, GPR119 and CD36. Expression of A) FFAR1 and C) GPR119 was 
increased in response to lipid infusion in all groups (*P ≤ 0.05), whereas D) CD36 and B) FFAR4 expression was unchanged. Data are mean ± SEM.  
Lean (n = 20), overweight (n = 18), obese (n = 18). 
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4.5.3 Blood glucose and plasma GI hormone concentrations 
Baseline blood glucose and plasma GLP-1, insulin and leptin concentrations were higher in 
the obese compared with lean and overweight groups (Table 4.3), without any difference 
between the latter groups. Baseline CCK, PYY and GIP concentrations did not differ 
between the groups. Blood glucose and plasma leptin concentrations were unchanged after 
ID lipid, but plasma CCK, PYY, GLP-1, GIP and insulin concentrations increased in all 
groups (iAUC P ≤ 0.05, Table 4.4, Figure 4.3), with no difference between the groups 
(Table 4.4). Peak blood glucose, plasma insulin and leptin concentrations in response to ID 
lipid were higher in the obese compared with the lean (CMax, P ≤ 0.01 for all) and the 
overweight (P ≤ 0.01 for all) groups, with no difference between lean and overweight. Peak 
CCK, PYY, GLP-1, and GIP concentrations did not differ between the groups (Table 4.4).  
 
Table 4.3: Fasted plasma gut hormone concentrations 
Baseline Lean Overweight Obese P 
Blood glucose (mmol/L) 5.4 ± 0.1 5.4 ± 0.1 6.0 ± 0.1 # ˄ 
# ≤ 0.001 
˄ ≤ 0.001 
CCK (pmol/L) 3.0 ± 0.3 3.2 ± 0.4 2.6 ± 0.3 NS 
GLP-1 (pg/mL) 33 ± 4 49 ± 6 72 ± 8 # ˄ 
# ≤ 0.001 
˄ ≤ 0.05 
GIP (pg/mL) 23 ± 3 22 ± 3 25 ± 4 NS 
PYY (pg/mL) 46 ± 8 62 ± 23 46 ± 6 NS 
Insulin (pg/mL) 196 ± 21 223 ± 31 450 ± 74# ˄ 
# ≤ 0.01 
˄ ≤ 0.01 
Leptin (pg/mL) 3076 ± 919 5464 ± 1233 17047 ± 3835#˄ 
# ≤ 0.001 
˄ ≤ 0.01 
CCK, cholecystokinin; GIP, glucose-dependent insulinotropic peptide; GLP-1, 
glucagon-like peptide-1; PYY, peptide YY. #Obese vs lean; ^Obese vs overweight. Data are 
mean ± SEM; lean, n = 19; overweight, n = 17; obese, n = 18. 
 
 




Table 4.4: Plasma gut hormone and blood glucose concentrations in response to a 120 
min ID infusion of 10% Intralipid® (2 kcal/min). 
Post-infusion Lean Overweight Obese P 
Blood glucose (mmol/L) 
CMax (mmol/L) 
0.10 ± 0.03 
5.8 ± 0.1 
0.04 ± 0.02 
5.6 ± 0.1 
0.10 ± 0.05 
6.4 ± 0.1#˄ 
NS 
# ≤ 0.01, ˄ ≤ 0.001 
CCK iAUC (pmol/L) 
CMax (pmol/L) 
3.1 ± 0.4 
8 ± 0.6 
4.0 ± 0.5 
9 ± 1 
4.0 ± 0.3 
8 ± 1 
NS 
NS 
GLP-1 iAUC (pg/mL) 
CMax (pg/mL) 
75 ± 9 
173 ± 21 
89 ± 22 
222 ± 49 
75 ± 9 
206 ± 19 
NS 
NS 
GIP iAUC (pg/mL) 
CMax (pg/mL) 
148 ± 21 
264 ± 34 
150 ± 22 
278 ± 35 
163 ± 15 
295 ± 22 
NS 
NS 
PYY iAUC (pg/mL) 
CMax (pg/mL) 
28  ± 6 
118 ± 12 
29  ± 8 
123 ± 18 
49  ± 7 
134 ± 10 
NS 
NS 
Insulin iAUC (pg/mL) 
CMax (pg/mL) 
142 ± 45 
395 ± 54 
84 ± 20 
425 ± 57 
163 ± 35 
868 ± 125#˄ 
NS 
#˄ ≤ 0.001 
Leptin iAUC (pg/mL) 
CMax (pg/mL) 
232 ± 117 
3632 ± 1012 
503 ± 195 
6716 ± 1538 
1432 ± 417# 
21001 ± 4893#˄ 
# ≤ 0.01 
# ≤ 0.001, ˄≤ 0.01 
CCK, cholecystokinin; CMax, concentration maximum; GIP, glucose-dependent 
insulinotropic peptide; GLP-1, glucagon-like peptide-1; iAUC, incremental AUC; PYY, 
peptide YY. #Obese vs lean; ^Obese vs overweight. Data are mean ± SEM; lean, n = 19; 
overweight, n = 17; obese, n = 18. 
 
4.5.4 Appetite perceptions and ad libitum energy and macronutrient intake 
Baseline appetite perception scores for hunger and fullness were similar in all study groups 
and did not change in response to ID lipid. The proportion of energy consumed as fat at the 
ad libitum buffet meal was higher in the obese compared with the overweight group (36 ± 
2% vs. 29 ± 2%, P ≤ 0.01), with no difference between the obese and lean, or the lean and 
overweight, groups. Lower carbohydrate consumption (% of energy) was also evident in the 
obese, compared with the overweight group (P ≤ 0.05). Energy intake, amount consumed 
and protein intakes at the buffet meal did not differ between groups (Table 4.2). 
  






Figure 4.3: Intralipid®-induced changes in plasma hormones and gut peptides. Relative 
to baseline, concentrations of A) CCK, B) GLP-1, C) GIP, D) PYY and E) insulin were 
increased by lipid infusion over 120 min (group comparisons of baseline and iAUC values 
are presented in Table 4.4 of the manuscript) with similar responses in all study groups. 
Plasma F) leptin concentrations were unchanged during lipid infusion. Data are mean ± 
SEM.  
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4.5.5 Relationships between BMI and duodenal FFA sensor expression 
BMI was negatively related to baseline expression of both FFAR1 (r = -0.4, P ≤ 0.01, Figure 
4.4A) and FFAR4 (r = -0.3, P ≤ 0.01, Figure 4.4B) but unrelated to baseline expression of 
GPR119 (Figure 4.4C). BMI was positively related to baseline expression of CD36 (r = 0.5, 
P ≤ 0.001, Figure 4.4D). There was no relationship between BMI and the magnitude of the 
lipid-induced changes in duodenal FFA sensor expression. 
 
Figure 4.4: Relationships between BMI and duodenal expression of FFAR1, FFAR4, 
GPR119 and CD36. BMI was negatively associated with baseline expression of A) FFAR1 
(r = -0.4, P ≤ 0.01) and B) FFAR4 (r = -0.3, P ≤ 0.01) and positively associated with baseline 
D) CD36 expression (r = 0.5, P ≤ 0.001). C) GPR119 expression was unrelated to BMI.
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4.5.6 Relationships between habitual dietary intake, and BMI and duodenal 
FFA sensor expression  
No relationships were evident between habitual dietary energy or macronutrient intakes and 
BMI. There were also no relationships evident between habitual energy or macronutrient 
intakes and the expression of duodenal lipid sensors at baseline, or following ID lipid 
infusion. 
 
4.5.7 Relationships of blood glucose and gut hormones, with BMI and 
duodenal FFA sensor expression  
BMI was positively related to baseline concentrations of blood glucose (r = 0.5, P ≤ 0.01), 
plasma GLP-1 (r = 0.5, P ≤ 0.01), insulin (r = 0.6, P ≤ 0.001) and leptin (r = 0.7, P ≤ 0.001). 
In contrast, baseline plasma CCK, PYY and GIP concentrations were unrelated to BMI. 
Lipid-stimulated PYY concentrations were positively related to BMI (iAUC r = 0.4, P ≤ 
0.05, Figure 4.5), however, no relationships were evident between changes in CCK, GLP-1 
or GIP and BMI. There was a positive relationship between lipid-induced changes in FFAR1 
expression with plasma GIP across all study groups (iAUC, r = 0.3, P ≤ 0.05, Figure 4.6). 
This correlation was largely due to the strength of the relationship in the overweight group 
(r = 0.7, P ≤ 0.05), and was not apparent in analyses limited to the lean or obese groups. 
There were no other relationships between expression of duodenal FFA sensors, with 
baseline or lipid-induced hormone concentrations.  
 
  











Figure 4.5: Relationship between Intralipid®-induced changes in PYY and BMI.  As a 
cohort, the change in PYY secretion from baseline in response to ID lipid infusion was 










Figure 4.6: Relationship between Intralipid®-induced changes in duodenal FFAR1 
expression and GIP secretion. As a cohort, the change in FFAR1 expression in response 
to lipid infusion was positively associated with plasma GIP concentration (iAUC r = 0.3, P 
≤ 0.05). This correlation emerged particularly from the overweight group (r = 0.7, P ≤ 0.05), 
as both lean and overweight groups alone did not reach a significant correlation (P = 0.1 and 
0.4 respectively). 
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4.5.8 Relationship of buffet meal energy and macronutrient intakes with BMI 
and duodenal FFA sensor expression 
The proportion of energy consumed as fat at the buffet meal was positively related to BMI 
(r = 0.4, P ≤ 0.01), however, total energy intake, total amount of food eaten, and protein or 
carbohydrate consumed at the buffet meal were unrelated to BMI. The expression of FFA 
sensors at baseline, or following ID lipid, was unrelated to total energy intake, total amount 
of food eaten, or protein, fat or carbohydrate consumed at the buffet meal.  
 
4.6 Discussion 
This study examined the effects of acute ID lipid on duodenal expression of the FFA sensors 
FFAR1, FFAR4, GPR119 and CD36 in lean, overweight and obese humans. Compared to 
lean participants, obese participants had increased CD36 expression, and decreased FFAR1 
and FFAR4 expression at baseline. FFAR1 expression was also decreased in overweight 
compared to lean participants. GPR119 and FFAR1 were positive and early transcriptional 
responders to ID lipid infusion, and their expression was increased to a similar extent in all 
study groups. In contrast, expression of CD36 and FFAR4 was unchanged by ID lipid. 
Lipid-induced gut hormone secretion was comparable across study groups. Interestingly, 
participants with the largest lipid-stimulated increase in FFAR1 expression had higher 
plasma GIP levels, supporting a role for FFAR1 in GIP secretion in humans. Finally, the 
proportion of energy consumed as fat at the buffet meal was higher in the obese group. 
Further research is required to establish whether dysregulation of duodenal FFA sensors is 
intrinsic to human obesity or results from chronic overconsumption of fat.  
 




The reduced FFAR1 and FFAR4 expression seen in obese participants may explain, in part, 
the lower intestinal fat sensitivity reported in human obesity127. It is known that knockdown 
of FFAR4 in cell lines and in rodents attenuates LCFA-induced GLP-1 and CCK 
secretion27,28. Furthermore, FFAR4 KO mice fed a HFD also develop obesity, glucose 
intolerance, and insulin resistance27,28. In humans, a FFAR4 loss-of-function polymorphism 
(R270H) increases the risk of developing obesity and insulin resistance in European 
populations, and when transfected into the human endocrine cell line, NCI-H716, attenuates 
GLP-1 secretion35. We previously demonstrated a positive association between FFAR4 
expression and BMI153, however, these outcomes, which appear contradictory to the 
outcomes in the current study, were probably due to notable differences in study design, 
including the use of a cross-section of patients attending the endoscopy unit with various, 
systemic co-morbidities (non-GI), including morbid obesity (BMI > 60) and differences in 
PCR methods. Nevertheless, these difference in FFAR4 data highlight the potential for 
plasticity of this FFA sensor in disease states. 
 
FFAR1 stimulates insulin secretion via direct actions on pancreatic β-cells, and indirectly by 
augmenting incretin hormone release from the intestine38,39. We showed that obese 
individuals had the lowest FFAR1 expression at baseline, while lipid-induced increases in 
FFAR1 were associated with higher plasma GIP levels across the cohort, and were strongest 
in the overweight group, possibly a compensation to preserve FFAR1-GIP signalling at 
similar levels to those in lean participants. Low fasting FFAR1 may be an adaptation in obese 
individuals to the long-term negative effects of dietary FFAs on insulin secretion, to 
re-establish homeostasis under conditions of excess caloric intake182,183. Importantly, the 
protective effects of FFAR1 deletion against metabolic dysfunction in HFD-fed mice 
remains controversial41,45, and consequences of chronic alterations in FFAR1 in humans 
require further investigation.  




GPR119 was expressed independent of BMI in the current study. We showed earlier that 
baseline GPR119 expression was negatively related to habitual PUFA consumption in lean 
participants179. The present findings included one individual whose data weakened the 
otherwise strong trend to the same correlation (r = -0.3, P = 0.06). While further 
investigations are needed to link chronic HFD consumption with FFA-sensor expression, 
this finding indicates that the type of fat, rather than fat consumption per se, may influence 
duodenal GPR119 expression. Relationships between GPR119 and hormone secretion have 
described, for example, RNA interference of GPR119 resulting in modestly reduced 
expression (23%) in murine endocrine cell lines (GLUTag) attenuated GLP-1 secretion46, 
while antagonising GLP-1 in mice attenuated the glucoregulatory effects of the GPR119 
agonist, AR2314650. In humans, infusion of GPR119-specific ligands, including 
2-oleoylglycerol, enhanced the secretion of GLP-1 and GIP151. 
 
While baseline CD36 expression was higher in the obese, several lines of evidence suggest 
that LCFA transport is not the primary mode of action of CD36, suggesting that alterations 
in CD36 may have broader implications for lipid metabolism. For example, CD36 protein 
expression on enterocytes is reduced as early as 1 hour following FFA exposure, as CD36 is 
rapidly ubiquinated184. Moreover, while deletion of CD36 from enterocytes in the proximal 
intestine of mice attenuates LCFA uptake152, LCFA absorption is unaffected in 
CD36-deficient mice184. CD36, however, is vital in the formation of chylomicrons, which 
are critical for LCFA-induced CCK secretion, gastric emptying and food intake, and plasma 
lipid transport184,185. In mice with diet-induced metabolic syndrome, dysregulated sensing of 
lipid by CD36 results in altered chylomicron formation, and postprandial 
hypertriglyceridaemia186. Indeed, postprandial hyperlipidaemia in humans with CD36 
deficiency has been primarily linked to an impairment of triglyceride metabolism135. 




Therefore increased CD36 expression may reflect post-absorptive defects in lipid 
metabolism, rather than enhanced LCFA uptake. 
 
Limitations 
Our study design of acute ID lipid infusion was based on our work investigating the effects 
of glycaemic state and glucose exposure on STRs in the human duodenum1,61, which 
revealed transcriptional regulation of STRs within 30 min of ID glucose, with functional 
links to glucose absorption1,61. The current study, however, cannot exclude the possibility 
that larger changes in expression of FFA sensors may occur over a longer duration of 
postprandial exposure to dietary lipid and other nutrients, or in response to a higher nutrient 
load. While we assessed transcriptional changes in the current study, confirmation of these 
changes at the protein level will add further support. However, this analysis will require 
verified, commercial antibodies for human use, which are not currently available. Reported 
dietary intakes did not differ between groups, although there are known limitations with 




This study demonstrated differences in the transcriptional regulation of FFA sensors, 
FFAR1, FFAR4, GPR119 and CD36 in the human duodenum in obesity. Further 
investigations into the in vivo consequences of altered expression of these targets in obesity 
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Background and aims: Enteroendocrine cells in the small intestine express STRs (a 
heterodimer of T1R2 + T1R3) which are tuned to detect all sweet stimuli, and can, in turn, 
regulate postprandial glycaemia by enhancing insulin secretion (i.e., the “incretin” effect) 
and increase glucose absorption by augmenting expression and function of the glucose 
transporter SGLT-1. In diet-controlled T2D patients with ‘well’ controlled glycaemia 
(WC-T2D), the intestinal STR system at euglycaemia responds similarly to healthy 
individuals, yet at hyperglycaemia, there is an impairment in transcriptional regulation of 
T1R2 and exaggerated glucose absorption. It is unknown, however, whether the prevailing 
hyperglycaemia in ‘poorly’ controlled T2D (PC-T2D), has more profound effects on the 
intestinal STR system with exaggerated consequences for postprandial glycaemic control. 
 
Materials and methods: Twelve healthy individuals, 12 patients with WC-T2D (HbA1c 
6.3 ± 0.2%), and 9 patients with PC-T2D (HbA1c 10.6 ± 0.5%) undertook an OGTT 
following an overnight fast, as previously described1. The participants were then studied 
during a euglycaemic clamp (5 ± 1 mmol/L), with duodenal biopsies collected at baseline 
(fasted) and after a 30-min ID glucose infusion (4 kcal/min). Copy numbers of T1R2, 
SGLT-1 and GLUT2 transcript were assessed at t = 0, 10 and 30 min by RT-PCR. Plasma 
concentrations of GIP, GLP-1, and C-peptide were measured at 10-min intervals from 
baseline (t = 0 min) for 60 min (t = 60 min). Plasma concentrations of 3-OMG were measured 
at t = 30 and 60 min, using mass spectrometry, to assess capacity for glucose absorption.  
 
Results: PC-T2D patients had higher blood glucose concentrations during the OGTT, at all 
times, compared to WC-T2D and HC groups (P ≤ 0.001), while WC-T2D patients had higher 
blood glucose beyond t = 30 min compared to the HC group (P ≤ 0.001). Basal SGLT-1 
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transcripts were lower in PC-T2D patients than in WC-T2D (2-fold, P ≤ 0.01), and GLUT2 
transcripts 3-4 fold lower than in HC and WC-T2D groups (both P ≤ 0.01). Transporter 
expression did not differ between HC and WC-T2D groups, while basal T1R2 expression 
was similar across all groups. Fasting concentrations of GLP-1 and C-peptide did not differ 
between groups, whereas GIP was higher in WC-T2D patients than in the HC group (P ≤ 
0.01). Glucose infusion increased SGLT-1 and decreased GLUT2 transcripts at 10 min 
(group × time interaction) in both HC and WC-T2D groups (both P ≤ 0.001, P ≤ 0.05 
respectively), but not in PC-T2D patients. When corrected for baseline, T1R2 transcripts 
were lower in PC-T2D patients after 10 min compared to WC-T2D (P ≤ 0.05). All transcript 
levels were similar to basal levels at 30 min, and did not differ between groups. ID glucose 
increased plasma GIP, GLP-1 and C-peptide in all groups (all P ≤ 0.001). GIP 
concentrations, however, were higher in both T2D groups than in HC; at 20, 40, 50 and 60 
min in WC-T2D (P ≤ 0.05), and t = 10 to 30 min in PC-T2D (P ≤ 0.01). Accordingly, GIP 
iAUC was increased in PC-T2D patients. GLP-1 concentrations were similar between PC-
T2D and HC groups, but were higher in the WC-T2D group than in PC-T2D and HC groups 
between 30-50 min (P ≤ 0.05), with correspondingly higher iAUC (WC-T2D vs. PC-T2D, 
P ≤ 0.05). C-peptide concentrations were lower in both T2D groups at 30 min compared to 
the HC group (P ≤ 0.01) and in PC-T2D at 60 min compared to both HC (P ≤ 0.01) and WC-
T2D groups (P ≤ 0.05). C-peptide iAUC was higher in HC then either T2D group (P ≤ 0.05).  
 
Conclusions: Glucose absorption is increased in patients with PC-T2D at euglycaemia, as 
and is likely to arise due to a loss of transcriptional regulation of SGLT-1 and GLUT2, and 
augmented cellular accumulation of SGLT-1 and GLUT2 protein. Increased glucose 
absorption in PC-T2D patients, together with preserved GIP responses, but lower GLP-1 and 
C-peptide responses, could exacerbate hyperglycaemia, and may be linked to impaired 
sensing of luminal glucose by duodenal T1R2. 




The presence of carbohydrates within the small intestine generates neural and hormonal 
signals that play a key role in the regulation of postprandial glycaemia. In particular, the 
secretion of the incretin hormones GIP and GLP-1 from intestinal enteroendocrine cells 
accounts for ~70% of the insulin released in response to enteral glucose in healthy 
individuals, compared to insulin responses to an isoglycaemic IV glucose stimulus188. In 
patients with T2D, the incretin effect is impaired189, due to a markedly diminished 
insulinotropic effect of GIP190 and, in some cases, reduced GLP-1 secretion107. Importantly, 
there is also evidence of an enhanced capacity to absorb glucose in both animal models of 
T2D and in patients with T2D61,64,191-193. However, while the incretin hormones are a critical 
determinant of postprandial glycaemia, the contribution of glucose sensing and absorption 
within the gut and their subsequent effects on glycaemic control in patients with T2D, is 
poorly understood. 
 
STRs, a heterodimer of the G-protein coupled receptors T1R2 and T1R3, are localised to the 
BBM of a subset of intestinal enteroendocrine cells57,61. Intestinal STRs detect the presence 
of luminal sweet stimuli and initiate a cascade of intracellular signaling events, resulting in 
cell depolarisation and the basolateral secretion of the incretin hormones, as well as the 
intestinotrophic peptide hormone, GLP-260,72,194. Mice lacking either T1R3 or the 
taste-specific G-protein, α-gustducin, have attenuated glucose-stimulated GLP-1 secretion59. 
Although less established in humans, intestinal STRs have been shown to participate in 
glucose-stimulated GLP-1 secretion in humans as this secretion is dose-dependently 
attenuated by blockade of intestinal STRs by the carboxylic acid lactisole30,195. STRs have 
also been linked to regulation of the primary intestinal glucose transporter, SGLT-1, 
localised to the BBM of intestinal enterocytes. The secretion of GLP-2 is a likely mechanism, 
as it is co-secreted with GLP-1 in an STR-dependent manner, and positively regulates the 
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expression of SGLT-1 in rodents, and in patients with short-bowel syndrome103,120,194,196. 
Increased SGLT-1 expression increases the capacity for glucose absorption at the 
BBM59,61,91,93,194, which is matched by an increase in facilitated glucose transport to the 
portal circulation via the basolaterally located, facilitative GLUT2 transporter197. As such, 
STRs have the capacity to direct glycaemia through actions on incretin hormone release, or 
by regulating SGLT-1 availability for glucose absorption, via GLP-2.  
 
We recently demonstrated that duodenal expression of T1R2 was similar in healthy 
individuals and patients with diet-controlled T2D at baseline euglycaemia, and that in both 
groups, T1R2 expression was rapidly upregulated in response to luminal glucose infusion. 
In contrast, at hyperglycaemia, while T1R2 expression was downregulated by enteral 
glucose in healthy individuals, it remained elevated in patients with T2D. This was linked to 
augmented glucose absorption, as assessed by increased absorption of the non-metabolisable 
glucose analogue, 3-OMG, which serves as a marker of glucose absorption and is transported 
by SGLT-11. Importantly, patients with PC-T2D commonly have elevated glycated 
haemoglobin (HbA1c) and hyperglycaemia, and remain at higher risk of diabetic 
complications, despite the provision of standardised treatments198-200. While HbA1C is 
strongly influenced by postprandial glycaemia in T2D patients201, the contribution of 
intestinal glucose absorption is underappreciated and poorly understood. It is therefore of 
interest to investigate whether PC-T2D patients demonstrate more profound defects in the 
intestinal STR system, and whether this equates to increased risk of postprandial 
hyperglycaemia.  
 
It is critical that we develop a better understanding of the influence of longstanding 
hyperglycaemia on the transcriptional regulation of the STR system, and of SGLT-1 and 
GLUT2, since this has the potential to identify new targets for therapy in patients with 
Duodenal sweet taste sensors in type 2 diabetes Chapter 5 
 
86 
PC-T2D. We, therefore, characterised the duodenal expression of T1R2, SGLT-1 and 
GLUT2 at euglycaemia in healthy individuals, and in patients with both WC-T2D and 
PC-T2D. Changes in plasma incretins, C-peptide (a marker of insulin production), and 
glucose absorption were also assessed, together with transcriptional changes. We 
hypothesised that in response to enteral glucose, patients with PC-T2D would exhibit further 
defects in the regulation of intestinal STRs, SGLT-1 and GLUT2, impaired incretin 
responses, exaggerated glucose absorption, and increased blood glucose, when compared 
with patients with WC-T2D and HC individuals.  
 
5.3 Materials and methods 
5.3.1 Participants 
Twelve healthy individuals, 12 patients with WC-T2D (HbA1c 6.3 ± 0.2%), and 9 patients 
with PC-T2D (HbA1c 10.6 ± 0.5%) were recruited through existing departmental databases, 
newspaper advertisement, and flyers displayed at local universities and hospitals, and were 
screened for significant co-morbidities. World Health Organisation criteria were used to 
define those with WC-T2D (HbA1c ≤ 7%) from PC-T2D (HbA1C ≥ 9%, and ≤12%). 
Participant demographics are presented in Table 5.1. All had normal haemoglobin (> 135 
g/L) and ferritin (> 10 mcg/L), no history of GI disease, and had normal renal and liver 
function. All WC-T2D patients and four PC-T2D patients were managed by diet alone. The 
remaining five PC-T2D patients were metformin treated, which was withheld for 48 hr prior 
to the study day due to known effects of metformin on GLP-1 release202. The study protocol 
was approved by the Royal Adelaide Hospital Research Ethics Committee and carried out 
in accordance with the Declaration of Helsinki. After receiving verbal and written study 
information, all participants provided written, informed consent. 
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Table 5.1: Demographic, anthropometric and metabolic characteristics of study 
participants  
 HC WC-T2D PC-T2D P 
n 12 12 9  
Sex 10M : 2F 4M : 8F 9M P ≤ 0.01 
Age (years) 31 ± 3 65 ± 2 59 ± 3 *#P ≤ 0.05 
BMI (kg.m2) 25 ± 2 28 ± 1 31 ± 1 #P ≤ 0.05 
HbA1c (%)  6.3 ± 0.2 10.6 ± 0.5 ˄P ≤ 0.001 
Fasting blood glucose 
(mmol/L) 
5.9 ± 0.1 7.5 ± 0.4 12.7 ± 1.2 #˄P ≤ 0.05 
Duration of T2D (years)  5 ± 1 7 ± 3  
HC, healthy controls; WC-T2D, well-controlled type 2 diabetes; PC-T2D, 
poorly-controlled type 2 diabetes. Data are mean ± SEM. *WC-T2D vs HC, #PC-T2D vs 
HC, ˄WC-T2D vs PC-T2D.  
 
5.3.2 Oral glucose tolerance test 
All participants underwent an OGTT at a screening visit, as previously described1. Briefly, 
each participant attended the laboratory at 0830 hr following an overnight fast. An IV 
cannula was inserted for blood collection and participants consumed a glucose drink 
consisting of 75 g glucose dissolved in 300mL water, within 5 min. Blood was collected at 
t = 0, 30, 60, 120 and 180 min following the glucose drink, with blood glucose concentrations 
measured by portable glucometer (Medisense Precision QID, Abbott Laboratories, Bedford, 
MA, USA).  
 
5.3.3 Endoscopy protocol 
Participants attended the Gastrointestinal Investigation Unit at the Royal Adelaide Hospital, 
at 0830 hr following a standardised evening meal (400g beef lasagne, McCain Foods, 
Australia) and overnight fast from 1900 hr. On arrival, an IV cannula was positioned into an 
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antecubital vein of each arm. Blood glucose was clamped at euglycaemia (5 mmol/L), first 
by administering a 50 mL IV bolus of 0.9% saline (Baxter Healthcare) for 1 min, then a 
continuous infusion at a rate of 150ml/hr, then 100 IU of insulin IV (Actrapid; Novo Nordisk, 
Baulkham Hills, NSW, Australia) in 500 mL of 4% succinylated gelatin solution 
(Gelofusine; B, Braun Australia, Bella Vista, NSW, Australia) administered at a variable 
rate to maintain euglycaemia.  A 25% dextrose solution was administered if blood glucose 
fell below 5 mmol/L. 
 
Once blood glucose concentrations were at stable euglycaemia for 30 min, a small-diameter 
video endoscope (GIF-XP160, Olympus, Tokyo, Japan) was inserted into an anaesthetised 
nostril to the second part of the duodenum, and 2 duodenal biopsies collected using standard 
biopsy forceps, and placed in RNAlater (Qiagen, Sydney, Australia). After baseline 
collection (t = 0 min), an ID glucose infusion was commenced via the biopsy channel of the 
endoscope (30g glucose with 3g 3-OMG, Sigma-Aldrich, St. Louis, MO; in water to a total 
volume of 150 mL, 4 kcal/min (total: 120 kcal)), and maintained for 30 min. At t = 10 min, 
the infusion was paused for 1 min and 2 additional biopsies taken. At t = 30 minutes, 2 final 
biopsies were taken and the endoscope removed. Blood samples (20 mL) were collected 
every 10 min for 1 hour (t = 0 - 60 min), with IV insulin and glucose infusions terminated at 
t = 60 min. Plasma or serum were separated from whole blood by centrifugation (15 min at 
4°C), within 15 min of collection, and stored at -80˚C for later analysis. Participants were 
then given a meal and blood glucose was checked to exclude hypoglycaemia (≤ 4 mmol/L), 
prior to them leaving the hospital. 
 




5.4.1 Quantification of T1R2, SGLT-1 and GLUT2 expression by RT-PCR 
 
Total RNA was extracted from a biopsy at each time point using the PureLinkTM MicroKit 
(Invitrogen, Thermo Fisher Scientific, Australia) as per the manufacturer instructions. The 
other biopsy was placed into archival storage. RNA quantity was determined using a 
NanodropTM Lite Spectrophotometer (Thermo Fisher Scientific, Australia) and purity 
assessed using A260/A280 ratio. Absolute standard curves were generated by including known 
copy number standards for each target in each RT-PCR assay (Table 5.2), as described 
previously61. RT-PCR was performed using a QuantiTect® SYBR Green® one-step RT-PCR 
kit (Qiagen) and 7500 fast Real-Time PCR system (Applied Biosystems, Thermo Fisher 
Scientific) according to the manufacturer’s specifications. Each assay was performed in 
triplicate and included no-template, and no reverse-transcription controls. Validated human 
primers for T1R2, SGLT-1 and GLUT2 were used (Table 5.3) (QuantiTect®, Qiagen). All 
replicates were averaged for final mRNA copy number, which was expressed as copies per 
25 ng of total RNA.  
 
Table 5.2: Human primers used to generate RT-PCR products containing the target 
amplicon to create absolute standard curves  
Gene Forward primer (5’ to 3’) Reverse primer (5’ to 3’) 
Amplicon 
(bp) 
T1R2 TACCTGCCTGGGGATTAC AAATAGGGAGAGGAAGTTGG 390 
SGLT-1 TGGAATGCCCTGGTTTTGGT GGAAGATGTGGAAGGAGTCGG 493 
GLUT2 ACCCTGGTTTTCACTGTCATCA AATTAGCCCACAATATAGTCCTGA 480 
T1R2, taste receptor type 1, member 2; SGLT-1, sodium-glucose co-transporter-1; GLUT2, glucose 
transporter-2; bp, base pairs. 
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Table 5.3: Human primers used for absolute quantification of SGLT-1, T1R2 and GLUT2 by 
RT-PCR 
Gene Primer information Amplicon (bp) 
T1R2 QT01026508 94 
SGLT-1 QT00001246 81 
GLUT2 QT01008399 88 
QT = QuantiTect® primer assay (Qiagen) 
 
5.4.2 Plasma GLP-1, GIP, C-Peptide and serum 3-OMG assays 
Total plasma GLP-1 was measured by RIA (GLPIT-36HK, Millipore, Billerica, MA). The 
minimum detectable limit was 3 pmol/L, and intra-, and inter-, assay CVs were 5.3% and 
8.1%, respectively. Plasma GIP was measured by radioimmunoassay using a modified 
version of a previously published method203. The standard curve was prepared in buffer and 
the radio-iodinated label was supplied by Perkin Elmer (Boston, MA).  The minimum 
detectable limit was 2 pmol/L, and intra- and inter-assay CVs were 9.6% and 8.6%, 
respectively. C-peptide was measured by ELISA immunoassay (10-1136-01, Mercodia, 
Uppsala, Sweden). The sensitivity of the assay was 15 pmol/L, and intra- and inter-assay 
CVs were 5.2% and 5.7%, respectively. Serum 3-OMG concentrations were measured by 
commercial liquid chromatography mass spectrometry with assay sensitivity of 10 pmol/L1, 
204.  
 
5.4.3 Data and statistical analyses  
Statistical analysis was performed using SPSS® software (SPSS Inc, IBM®, version 20). A 
one-way ANOVA, with group as a factor, was used to determine differences in age, BMI, 
and fasting blood glucose at the screening visit. Sex distribution across groups was assessed 
using Fishers Exact test (Chi-squared). Differences in HbA1C (%) between WC-T2D and 
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PC-T2D groups was assessed using an independent samples t-test. Basal transcripts, and 
transcript changes in response to glucose of T1R2, SGLT-1 and GLUT2 in response to ID 
glucose were assessed by two-way repeated measures ANOVA, with group, and time, as 
factors. Due to inter-subject variability in transcript levels, the responses to ID glucose were 
also assessed as change from baseline (t = 30 – 0 min), with group as the between-subjects 
factor. The iAUC for blood glucose, GIP, GLP-1 and C-Peptide was calculated using the 
trapezoidal rule from t = 0 - 180 min (blood glucose) and t = 0 - 60 min (gut hormones), and 
analysed by one-way ANOVA. A two-way, repeated measures ANOVA was also performed 
on these variables with time and group as factors. The maximum concentration (Cmax) of 
gut hormones were calculated from t = 0 - 120 min. Post-hoc pairwise comparisons, 
corrected for multiple comparisons using the Sidak method, was performed for all 
ANOVA’s that were significant. Relationships between transcript expression and blood 
glucose, GIP, GLP-1 and C-Peptide (iAUCs) were evaluated by Pearson’s correlation 
coefficient (r). GIP assays were incomplete at the time of thesis preparation (PC-T2D, n = 
3). There was low signal detection for GIP in n = 2 HC, and n = 2 WC-T2D participants, 
which were excluded from analysis. GLP-1 was below signal detection for n = 1 HC 
participant, which was similarly excluded. Statistical significance was accepted at P ≤ 0.05. 
Data are expressed as mean ± SEM. 
  




The procedures were well tolerated and biopsies were collected from all participants.  
 
5.5.1 Blood glucose concentrations during the OGTT 
 
Blood glucose increased in response to the glucose drink in all groups (P ≤ 0.001), and was 
highest in PC-T2D patients compared with HC participants and WC-T2D patients at all time 
points (P ≤ 0.001). Blood glucose in the WC-T2D group was also higher than in the HC 
group beyond t = 30 min (P ≤ 0.001, Figure 5.1). Blood glucose iAUC was higher in 
PC-T2D patients than in both HC and WC-T2D groups (P ≤ 0.001), with the HC group also 
lower in comparison to the WC-T2D group (P ≤ 0.05).   
 
5.5.2 Baseline T1R2, SGLT-1 and GLUT2 expression in the proximal human 
duodenum  
T1R2, SGLT-1 and GLUT2 transcripts were detected in all duodenal biopsies at baseline, 
with abundance SGLT>>GLUT2>T1R2 in all groups (Figure 5.2). T1R2 transcript levels 
at baseline did not differ between groups. Baseline SGLT-1 transcript levels were 1.8-fold 
lower in PC-T2D, compared to WC-T2D (P ≤ 0.01). Baseline GLUT2 transcript levels were 
3.8-, and 3.4-fold lower in PC-T2D compared to HC (P ≤ 0.01) and WC-T2D (P ≤ 0.01), 
respectively. Baseline transcript levels of T1R2, SGLT-1 and GLUT2 did not differ between 



























Figure 5.1: Blood glucose concentrations during the OGTT. Consumption of glucose 
drink increased blood glucose concentrations in all groups (P ≤0.001), with higher 
concentrations in PC-T2D patients at all time points compared with both HC and WC-T2D 
groups (P ≤ 0.001), and in WC-T2D compared with HC from t = 30 min onwards (P ≤ 0.001).  
Data are mean ± SEM. *WC-T2D vs HC, #PC-T2D vs HC, ˄WC-T2D vs PC-T2D. HC, 
healthy controls; PC-T2D, poorly-controlled type 2 diabetes; WC-T2D, well-controlled type 
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Figure 5.2: Duodenal transcript levels of T1R2, SGLT-1 and GLUT2 in HC, WC-T2D 
and PC-T2D groups at baseline. A) T1R2 transcripts did not differ between groups at 
baseline. B) SGLT-1 transcripts were 1.8-fold lower in PC-T2D compared to the WC-T2D 
group (P ≤ 0.01). C) GLUT2 transcripts were 3.8 and 3.4-fold lower in PC-T2D compared 
to HC (P ≤ 0.01) and WC-T2D (P ≤ 0.01) groups, respectively. Data are mean ± SEM. HC, 
healthy controls; PC-T2D, poorly controlled type 2 diabetes; WC-T2D, well controlled type 
2 diabetes. #PC-T2D vs HC; ^WC-T2D vs PC-T2D. HC, n = 11; WC-T2D, n = 12; PC-T2D, 
n = 9 (T1R2, n = 8).  
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5.5.3 Effects of ID glucose on expression of T1R2, SGLT-1 and GLUT2  
T1R2 transcript levels did not change in response to ID glucose in subject groups, but when 
assessed as change from baseline, were lower in the PC-T2D group at 10 min compared to 
other groups (group × time interaction, P ≤ 0.05). T1R2 levels were unchanged from baseline 
at t = 30 min, and were not different between groups (Figure 5.3A). 
 
SGLT-1 transcript levels were higher in HC and WC-T2D subjects after 10 min of ID 
glucose than in PC-T2D subjects (group × time interactions, P ≤ 0.001), whereas levels were 
similar across groups at 30 min. The increase in SGLT-1 transcripts from baseline was larger 
in the HC group at t = 10 min compared to the WC-T2D (P ≤ 0.05) and PC-T2D groups (P 
≤ 0.01), with no difference between both T2D groups. SGLT-1 levels were unchanged across 
all study groups at 30 min (Figure 5.3B). 
 
GLUT2 transcripts were similar and lower in HC (P ≤ 0.01) and PC-T2D subjects (P ≤ 0.05) 
compared to WC-T2D subjects after 10 min of ID glucose (group × time interactions). 
GLUT2 levels in HC subjects were similar to levels in WC-T2D subjects by 30 min, but 
remained lower in PC-T2D in comparison to these two groups (both P ≤ 0.05). When 
assessed as baseline changes, GLUT2 transcripts were significantly lower in both the HC (P 
≤ 0.001) and WC-T2D groups (P ≤ 0.05) compared to the PC-T2D group at 10 min, however 
GLUT2 levels were unchanged across all study groups at 30 min (Figure 5.3C).   




Figure 5.3: Glucose-induced changes in duodenal T1R2, SGLT-1 and GLUT2 
transcript levels in HC, WC-T2D and PC-T2D groups. A) The decrease in T1R2 
transcript copy number from baseline was larger in PC-T2D than in HC and WC-T2D at 10 
min (both P ≤ 0.05). B) At the same time SGLT-1 transcript numbers increased from baseline 
in the HC group compared with WC-T2D (P ≤ 0.05) and PC-T2D (P ≤ 0.01) groups, with 
no difference between the two T2D groups. C) GLUT2 transcripts decreased further in the 
HC (P ≤ 0.001) and WC-T2D groups (P ≤ 0.05) at 10 min than in the PC-T2D group. 
Transcripts of all targets were unchanged from baseline at 30 min. Data are mean ± SEM. 
HC, healthy controls; PC-T2D, poorly-controlled type 2 diabetes; WC-T2D, well-controlled 
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5.5.4 Plasma GIP, GLP-1 and C-peptide concentrations 
GIP concentrations were higher in the WC-T2D group at baseline compared to both the HC 
(P ≤ 0.01) and PC-T2D groups (P ≤ 0.05, Table 5.4), but similar in HC and PC-T2D groups. 
GIP increased in response to ID glucose in all groups (P ≤ 0.001, Figure 5.4A), and was 
higher in WC-T2D at t = 20 and between t = 40-60 min compared with the HC group (group 
× time interaction, P ≤ 0.05). GIP concentrations were also higher in the PC-T2D group than 
in the HC group from t = 10 to 30 min (P ≤ 0.01), and, accordingly, GIP iAUC was increased 
in PC-T2D (P ≤ 0.05, Table 5.5). GIP concentrations did not differ between the WC-T2D 
and PC-T2D groups during the infusion (Figure 5.4A). Peak GIP concentration (Cmax) did 
not differ between the T2D groups, but both WC-T2D and PC-T2D had higher peak 
concentrations than the HC group (P ≤ 0.05) (Table 5.5).  
 
Plasma GLP-1 concentrations were not different at baseline (Table 5.4) but increased in 
response to ID glucose in all groups (P ≤ 0.001, Figure 5.4B). GLP-1 concentrations were 
higher in the WC-T2D group between t = 30 to 60 min than in HC (group × time interaction, 
P ≤ 0.05) and between t = 30 to 50 min than in the PC-T2D group (P ≤ 0.01); GLP-1 
concentrations were not different between PC-T2D and HC groups throughout the study. 
The iAUC for GLP-1 was higher in WC-T2D than in the PC-T2D group (P ≤ 0.05; Table 
5.5), and showed a trend to be higher than in HC (P = 0.06). Peak GLP-1 concentration was 
higher in WC-T2D compared to HC and PC-T2D groups (both P ≤ 0.05), while peak levels 
in HC and PC-T2D groups did not differ (Table 5.5). 
 
Plasma C-peptide concentrations did not differ between groups at baseline (Table 5.4), but 
increased in response to ID glucose in all groups (P ≤ 0.001, Figure 5.4C). C-peptide was 
higher in the HC group than WC-T2D (group × time interaction, P ≤ 0.01) or PC-T2D  
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(P ≤ 0.001) groups at 30 min, with no differences between the T2D groups. At t = 60 min, 
C-peptide concentrations were not different between HC and WC-T2D groups, and 
significantly higher than concentrations in the PC-T2D group (P ≤ 0.05, P ≤ 0.01 
respectively, Figure 5.4C). The iAUC of C-peptide was higher in the HC group than 
WC-T2D (P ≤ 0.05) and PC-T2D groups (P ≤ 0.01), but did not differ between T2D groups. 
Peak C-peptide concentrations were higher in HC than the PC-T2D group (P ≤ 0.01), but 
were not different compared to WC-T2D, or between T2D groups (Table 5.5). 
 
Table 5.4: Baseline plasma concentrations of GIP, GLP-1, and C-peptide  
 HC WC-T2D PC-T2D P 
GIP1 (pmol/L) 9 ± 2 16 ± 2 10 ± 1 *˄P ≤ 0.01 
GLP-12 (pmol/L) 21 ± 1 23 ± 2 22 ± 2 NS 
C-peptide3 (pmol/L) 313 ± 49 327 ± 37 294 ± 38 NS 
HC, healthy controls; GIP, glucose-dependent insulinotropic polypeptide; GLP-1, 
glucagon-like peptide-1; PC-T2D, poorly-controlled type 2 diabetes; WC-T2D, well-
controlled type 2 diabetes. Data are mean ± SEM. *WC-T2D vs. HC; ̂ WC-T2D vs PC-T2D. 
1HC, n = 10; WC-T2D, n = 10; PC-T2D, n = 6, 2HC, n =11; WC-T2D, n = 12; PC-T2D, n = 
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Figure 5.4: Effects of ID glucose on plasma GIP, GLP-1 and C-peptide concentrations 
in HC, WC-T2D and PC-T2D groups. A) GIP B) GLP-1 and C) C-peptide concentrations 
increased in response to ID glucose in all groups (group × time interaction: P ≤ 0.001, for 
all). A) GIP was higher in WC-T2D (P ≤ 0.01) and PC-T2D (P ≤ 0.05) groups at baseline 
compared with the HC group. GIP concentrations remained elevated at t = 20, and between 
t = 40-60 min in WC-T2D compared with HC (P ≤ 0.05), and between t = 10-30 min in 
PC-T2D compared with HC (P ≤ 0.01). B) GLP-1 was higher in WC-T2D than the HC group 
between t = 30-60 (P ≤ 0.05), and higher than the PC-T2D group between 30-50 min (P ≤ 
0.01). C) C-peptide concentrations were higher in HC than WC-T2D (P ≤ 0.01) or PC-T2D 
groups at t = 30 min (P ≤ 0.001), but similar in HC and WC-T2D groups at 60 min, when 
both concentrations were higher than in the PC-T2D group (P ≤ 0.05, P ≤ 0.01 respectively).  
Data are mean ± SEM. HC, healthy controls; PC-T2D, poorly-controlled type 2 diabetes; 
WC-T2D, well-controlled type 2 diabetes. *WC-T2D vs HC; #PC-T2D vs HC; ^WC-T2D 
vs PC-T2D.  
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Table 5.5: Effects of 30-min ID glucose infusion (4 kcal/min) on plasma GIP, GLP-1 
and C-peptide concentrations. 





765 ± 104 
 
 
26 ± 3 
1008 ± 131 
 
 
40 ± 4 
1464 ± 234 
 
 
43 ± 5 
#P ≤ 0.05 
 
 





466 ± 183 
 
 
36 ± 5 
1045 ± 174 
 
 
56 ± 6 
369 ± 131 
 
 
35 ± 5 
˄P ≤ 0.01 
 
 





22540 ± 4017 
 
 
932 ± 140 
9621 ± 3439 
 
 
611 ± 86 
2060 ± 978 
 
 
361 ± 60 
*P ≤ 0.01, #P ≤ 0.001 
 
 
#P ≤ 0.01 
CMax, concentration maximum; GIP, glucose-dependent insulinotropic peptide; GLP-1, 
glucagon-like peptide-1; HC, healthy controls; iAUC, incremental AUC; PC-T2D, 
poorly-controlled type 2 diabetes; WC-T2D, well-controlled type 2 diabetes. Data are mean 
± SEM; *WC-T2D vs HC; #PC-T2D vs HC; ˄WC-T2D vs PC-T2D. 1HC, n = 10, WC-T2D, 
n = 10, PC-T2D, n = 6; 2HC, n = 11, WC-T2D, n = 12, PC-T2D, n = 8; 3HC, n = 12, WC-T2D, 
n = 12, PC-T2D, n = 8. 
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5.5.5 Serum 3-OMG concentrations 
Serum 3-OMG increased in response to ID glucose in all groups (P ≤ 0.001, Figure 5.5), but 
was significantly higher in PC-T2D after 30 min than in HC (P ≤ 0.05) and WC-T2D (P ≤ 
0.01) groups (group × time interactions). The iAUC for 3-OMG was higher in PC-T2D than 












Figure 5.5: Effect of ID glucose on serum 3-OMG concentrations. ID infusion increased 
serum 3-OMG concentrations in all groups (P ≤ 0.001), with higher levels in PC-T2D at 30 
min than HC (P ≤ 0.05) or WC-T2D groups (P ≤ 0.01).  Data are mean ± SEM. HC, healthy 
controls; PC-T2D, poorly-controlled type 2 diabetes; WC-T2D, well-controlled type 2 
diabetes. HC, n = 11; WC-T2D, n = 12; PC-T2D, n = 8. *WC-T2D vs HC, ˄WC-T2D vs 
PC-T2D. 
 
5.5.6 Relationships between variables 
Fasting blood glucose concentrations were positively related to HbA1C in both T2D groups 
(r = 0.7, P ≤ 0.01), and with age (r = 0.4, P ≤ 0.05) and BMI (r = 0.4, P ≤ 0.01) across the 
entire cohort. The iAUC of blood glucose also positively associated with HbA1C levels (r = 
0.7, P ≤ 0.01). There were no associations between fasting blood glucose with GIP, GLP-1 
or C-peptide at baseline. HbA1C was negatively related to basal GLUT2 (r = -0.7, P ≤ 0.01) 
and SGLT-1 transcript levels (r = -0.6, P ≤ 0.01) in T2D groups. A similar negative 
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association also existed between fasting blood glucose and basal GLUT2 transcript level  
(r = -0.5, P ≤ 0.01). Basal T1R2 transcript levels did not relate to any demographic factors. 
Baseline transcript levels of T1R2, SGLT-1 or GLUT2 were not associated with GIP, GLP-1 
or C-peptide concentrations.  
 
Levels of T1R2 or GLUT2 transcript at baseline, or their change during ID infusion, were 
unrelated to GIP, GLP-1 or C-peptide iAUC. GIP concentrations at 10 min were, however, 
were negatively related to basal SGLT-1 transcripts (r = -0.6, P ≤ 0.05), as was the degree 
of SGLT-1 transcript change during ID infusion (r = -0.5, P ≤ 0.05). C-peptide and blood 
glucose were negatively associated across the cohort (iAUCs, r = -0.5, P ≤ 0.01). There were 
no other associations between GIP, GLP-1, C-peptide, or blood glucose iAUCs.   
 
Serum 3-OMG concentrations were unrelated to duodenal transcript expression at 10 or 30 
min into glucose infusion across study groups. However, the change in T1R2 at 10 min was 
positively related to 3-OMG after 30 min in HC participants (r = 0.7, P ≤ 0.05). 3-OMG 
concentrations at 30 and 60 min were also positively associated with C-peptide concentration 
across the cohort (r = 0.4, P ≤ 0.05 and r = 0.5, P ≤ 0.01, respectively).  
 
5.6 Discussion 
This study investigated the effects of ID glucose on transcriptional regulation of intestinal 
T1R2, SGLT-1 and GLUT2, and whether these effects differed in patients with WC-T2D 
and PC-T2D, and had consequences for incretin secretion and glycaemic control. We 
demonstrated that T1R2 transcripts were similarly abundant in HC, WC-T2D and PC-T2D 
groups at baseline, extending our previous findings1. To our knowledge, our study is the first 
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to show that patients with PC-T2D had lower basal expression of SGLT-1 and GLUT2 than 
WC-T2D patients. In response to ID glucose, transcriptional regulation of SGLT-1 and 
GLUT2 was also attenuated in PC-T2D patients. By contrast, T1R2 expression decreased in 
response to ID glucose in PC-T2D, but not in HC or WC-T2D groups. Given that 1) glucose 
absorption (assessed by 3-OMG) was higher in PC-T2D patients, and 2) GIP responses were 
preserved, while 3) GLP-1 and C-peptide responses were lower, we propose that a loss of 
intestinal STR signalling fidelity in PC-T2D patients may impair their ability to 
appropriately regulate glucose absorption, and promote a GIP-led incretin response, both of 
which could exacerbate hyperglycaemia. 
 
Differences in prevailing glycaemia between HC participants, WC-T2D and PC-T2D 
patients did not influence intestinal T1R2 transcription at baseline. However, the transient 
downregulation of T1R2 upon ID glucose infusion in PC-T2D patients at euglycaemia 
paralleled T1R2 responses to ID glucose we had previously observed in HC participants 
during hyperglycaemia1. This may indicate a failure of glycaemic status to direct 
transcription of T1R2 by luminal glucose in PC-T2D patients, leading to altered luminal 
sensing by T1R2, and potentially, impaired coordination of glucose transport via SGLT-1. 
 
The lower expression of SGLT-1 at baseline in PC-T2D patients did not correspond with 
reduced glucose absorption. Rather, glucose absorption was higher in PC-T2D participants 
early and over the first hour, supporting a role for post-transcriptional modification of 
SGLT-1 as an early determinant of postprandial glucose absorption in these patients. This is 
supported by findings in Sprague-Dawley rats, where intestinal infusion of D-glucose for up 
to 3 hours upregulated SGLT-1 protein, but did not change mRNA expression65. 
Accordingly, post-transcriptional modification of SGLT-1 may have an under-appreciated 
Duodenal sweet taste sensors in type 2 diabetes Chapter 5 
 
104 
role in functional absorption in patients with PC-T2D, which will need to be confirmed in 
follow-up proteomic experiments. The loss of transcriptional regulation of SGLT-1 in 
PC-T2D patients contrasted the early upregulation of SGLT-1 in HC participants and 
WC-T2D patients, which paralleled glucose absorption. While further studies of SGLT-1 
protein kinetics in response to nutrient stimulation are required, a dissociation between 
luminal sweet sensing and transporter control may occur in PC-T2D, leading to a 
T1R2-independent, and post-transcriptional, gain in SGLT-1 absorptive capacity, and 
hyperglycaemia. Our evidence of exaggerated blood glucose excursions and lower C-peptide 
secretion in patients with PC-T2D is consistent with a progressive failure of GSIS with T2D 
disease progression.  
 
Together with a loss of transcriptional control of SGLT-1 in PC-T2D patients, 
glucose-induced GIP secretion is preserved in the presence of augmented glucose 
absorption. This mechanism may also underlie the attenuated GLP-1 secretion in patients 
with PC-T2D, due to reduced luminal glucose exposure to L-cells in the distal small 
intestine. In contrast, the increased glucose-induced GLP-1 response seen in WC-T2D 
patients with normal absorption supports the existence of increased duodenal L-cell density 
and augmented glucose-stimulated GLP-1 secretion, as reported in newly diagnosed T2D 
patients205. As such, an increase in L-cell density, and glucose-induced GLP-1 secretion, 
may be limited in patients with more severe diabetes, as evidenced in the current study and 
supported by an earlier report where 4 weeks of insulin therapy failed to restore postprandial 
GLP-1 secretion in a similar and poorly controlled T2D patient cohort206. While several 
studies have described attenuated GLP-1 secretion as a feature of patients with WC-T2D107, 
a recent meta-analysis has identified that patient-specific characteristics (e.g., age, body 
weight, fasting glucagon concentrations) exert a stronger influence on GLP-1 secretory 
responses. Such patient diversity may underpin reports of normal, and even augmented, 
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GLP-1 secretion in response to nutrient intake across T2D patient cohorts207. The GIP-led 
incretin response observed in our PC-T2D group, coupled with augmented glucose 
absorption, supports findings of studies in morbidly obese, non-diabetic participants exposed 
to a similar acute ID glucose stimulus208. Glucose absorption in these participants was 
markedly increased, in association with increased GIP secretion, but attenuated GLP-1 
secretion, and suppression of glucagon. This occurred in concert with increased SGLT-1 
expression, and led to hyperglycaemia and hyperinsulinaemia208. Although the directionality 
of SGLT-1 responses to glucose differed between non-diabetic, morbidly obese participants 
and non-obese diabetic participants, in both cases a GIP-led incretin response, attenuated 
GLP-1 secretion and augmented glucose absorption posed an increased risk for 
hyperglycaemia. Moreover, this combination with a loss of GSIS in patients with PC-T2D 
(attenuated C-peptide response) highlights multiple challenges for ongoing glycaemic 
homeostasis.  
 
We found no association between GLUT2 and incretin secretion, in accord with studies 
showing that incretin secretion is largely unaltered in GLUT2 KO mice98. However, based 
on evidence of similar GLUT2 changes at transcript and protein levels in islets of a mouse 
model of T2D209, the reduced intestinal GLUT2 expression after ID glucose in HC 
participants and WC-T2D patients may attenuate glucose egress from enterocytes. This 
could, in part, limit postprandial glycaemic excursions, as occurs in GLUT2 KO mice 
following intragastric gavage of glucose98. Together with SGLT-1 changes described in 
patients with PC-T2D, the absence of such a GLUT2 response could promote further 
hyperglycaemia, and indicate a failure to control glucose uptake and egress from intestinal 
enterocytes.  
 




Our study had a number of limitations. We did not quantify changes in protein levels of 
T1R2, SGLT-1 or GLUT2 in parallel to those of transcripts, however, similarly rapid 
changes in these proteins occur in the BBM of the rat jejunum in response to STR activation, 
while glucose absorption assessed by 3-OMG is expected to parallel function of SGLT-193. 
We also acknowledge that euglycaemia does not reflect a physiologically normal state for 
PC-T2D patients, and although recruitment of these patients was challenging, future studies 
should establish whether changes in the STR system also occurs during hyperglycaemia. 
This would enable determination of the significance of prevailing glycaemia on the intestinal 
STR system. However, even at the therapeutically desired euglycaemia, we showed that 
PC-T2D patients respond differently to luminal glucose cues with dysregulated control of 
intestinal T1R2, SGLT-1 and GLUT2 transcription. The short infusion time used was chosen 
to minimise discomfort to participants, but further transcript and protein changes for these 




This study has demonstrated that patients with PC-T2D have reduced basal expression of 
glucose transporters SGLT-1 and GLUT2 which then fail to undergo transcriptional 
regulation by ID glucose, in contrast to the responses observed in HC and WC-T2D 
participants. Despite this, PC-T2D patients showed augmented glucose absorption 
supporting a role for post-transcriptional control mechanism(s), and augmented cellular 
accumulation of SGLT-1 and GLUT2 as the basis of these absorptive gains. Together with 
preserved glucose-induced GIP release, but attenuated GLP-1 and C-peptide responses, 
these findings indicate that hyperglycaemia in patients with PC-T2D arises due to a 
convergence of augmented glucose absorption with an impaired, GIP-led incretin and insulin 
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response, which may be linked to impaired sensing of luminal glucose by duodenal T1R2. 
Future studies should investigate these responses under hyperglycaemic conditions in 
PC-T2D, including proteomics, to investigate the influence of prevailing glycaemia on the 
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The studies presented in this thesis have examined the roles of intestinal sensors and 
transporters for fatty acids in the impaired appetite control in obesity, and intestinal sensors 
and transporters for carbohydrates in the glycaemic dysregulation of patients with T2D, in 
comparison to healthy participants. These studies have revealed fundamental and underlying 
differences in their transcriptional regulation that improve understanding of connections 
between intestinal nutrients and energy/glycaemic homeostasis. Novel therapeutics that 
capitalise on these unique pathways of metabolic control hold the potential to improve 
management of these chronic human diseases.  
 
The study presented in Chapter 3 characterised the expression of the intestinal fat sensors 
FFAR1, FFAR4, GPR119, and the fatty acid transporter CD36, in the duodenum of healthy 
individuals before and after an acute ID lipid infusion. Associations between fasted, and 
lipid-induced changes in these targets with the secretion of GLP-1 and CCK, was also 
investigated. To determine the influence of habitual energy and macronutrient intake on 
fasting fat sensor expression, and the potential impact on intestinal fat sensitivity, analysis 
of habitual dietary patterns were also undertaken. This results of this study revealed that all 
targets were expressed in the duodenum, with their order of transcript abundance matched 
to their cellular distribution (e.g., highly abundant CD36 expression on intestinal 
enterocytes153). We also observed that GPR119 expression was negatively associated with 
habitual consumption of PUFAs in healthy individuals. Although long-term consumption of 
habitual fat and GPR119 expression in humans has not been studied, consumption of PUFA 
is linked with lower levels of adiposity171. Future investigations should look to characterise 
the role of dietary fatty acid composition on these intestinal FFAR pathways, and to 
determine whether dietary modifications may enhance their sensitivity and improve fat 
metabolism.  
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The study presented in Chapter 4 expanded on the findings in Chapter 3, by investigating 
the duodenal expression of FFAR1, FFAR4, GPR119 and CD36 across a broad BMI range 
in otherwise healthy individuals, and in response to acute ID lipid. The purpose of this design 
was to determine whether there was a reduced sensitivity to lipid with increasing BMI, as 
observed through the attenuation of satiety hormone secretion, and reduced suppression of 
appetite and energy intake, and to determine whether this was associated with transcriptional 
changes in duodenal fat sensors. The study revealed that BMI was positively associated with 
basal expression of CD36, but negatively associated with basal FFAR1 and FFAR4 
expression, while GPR119 expression was independent of BMI. As such, human obesity 
may lead to a progressive and reduced ability to adequately respond to ingested LCFAs, 
through reduced availability of FFAR1 and FFAR4. This is supported by human studies of 
a loss-of-function-variant of FFAR4, shown to be associated with increased risk of obesity 
and insulin resistance35. Furthermore, FFAR4 KO mice that are fed a HFD develop obesity, 
glucose intolerance, and insulin resistance27,28, indicating that a loss of FFAR4 has 
implications for obesity development. However, the metabolic implications for reduced 
FFAR1 in obesity remains unclear, as FFAR1 deletion in mice does not consistently protect 
against metabolic dysfunction in HFD-fed mice41,45, and as such requires further 
investigation. 
 
Although we found CD36 expression was increased in obese humans, the consequences for 
fatty acid transport is unclear, as knockdown of this transporter in mice does not affect 
overall LCFA absorption152,184. However, alterations in CD36 may impair postprandial 
triglyceride metabolism, as CD36 plays a vital role in the formation of lipid-rich 
chylomicrons, which are critical for the secretion of CCK in response to LCFAs, as well as 
gastric emptying, food intake, and plasma lipid transport52,135. Future experiments that will 
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analyse postprandial triglycerides in plasma are planned for this cohort, and will be related 
to changes in CD36 observed in the current dataset. 
 
Chapter 4 also confirmed that while basal FFAR1 expression was lower in obese 
participants, it increased in response to lipid in a BMI-independent manner. Moreover, this 
study provided the first evidence that FFAR1 expression was positively associated with 
augmented GIP secretion following ID lipid. This adds support to the previously reported 
role for FFAR1-stimulated insulin secretion from pancreatic β-cells in rodents38, and 
highlights a potential dual role for FFAR1 to augment postprandial insulin secretion in 
humans via direct (pancreatic) and indirect (intestinal GIP secretion) mechanisms. As in 
Chapter 3, GPR119 expression increased in response to ID lipid in a BMI-independent 
manner. As such, acute changes in GPR119 expression should be explored in future 
investigations, particularly in relation to the effect of lipid on plasma OEA, as OEA is a 
ligand for GPR119 and triggers the secretion of GLP-1 in both humans and rodent cell 
lines46, and has been linked to between-meal satiety in rodents163. Previous work has shown 
that the type and amount of habitual fat consumption is a predictor of intestinal OEA 
production, and thus capacity for GPR119 activation173. Analysis of the plasma OEA 
content, along with lipid content of the duodenal biopsies is planned for future studies by 
our group, and will provide a vital piece of information about the link between GPR119, 
OEA, and satiety in humans.  
 
Although we observed differences in the expression of FFAR1, FFAR4 and CD36 across 
BMI, this did not alter secretion of GLP-1, CCK and PYY across lean, overweight and obese 
participants. We did, however, note an increase in the proportion of energy consumed as fat 
at the buffet meal with increasing BMI, suggesting that individuals in the current study 
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represent an early phase of metabolic disruption, where they are still able to adequately 
compensate for increases in luminal fat exposure. It is possible that these responses would 
be altered in metabolically unhealthy obese, or T2D cohorts.  As such, it would be 
worthwhile to determine in future studies the effects of chronic HFD consumption on GI 
responses, and fat sensor expression, and whether fat sensors are susceptible to modifications 
to habitual dietary intake, and as such whether they represent novel targets for obesity 
treatment and prevention. 
 
The study presented in Chapter 5 focussed on the intestinal sweet taste system across 
patients with a range of T2D disease control. Our group had previously established that 
transcriptional regulation of the intestinal STR system was similar at euglycaemia in patients 
with diet-controlled T2D disease and healthy participants during ID glucose, but became 
disordered in T2D patients at hyperglycaemia1. This study investigated whether patients with 
prevailing hyperglycaemia and more advanced T2D disease had further impairments in the 
intestinal STR system and incretin responses, predisposing to worsened postprandial 
glycaemia. This study extended findings that intestinal T1R2 expression was unaffected by 
diabetic status, and revealed a profound loss of basal SGLT-1 and GLUT2 expression in 
PC-T2D patients. Moreover, intestinal SGLT-1 and GLUT2 was upregulated by ID glucose 
in HC participants and patients with WC-T2D at euglycaemia, but not in patients with 
PC-T2D. From this study it is also clear that post-transcriptional modification of SGLT-1, 
and GLUT2, may play a prominent role in functional glucose absorption in patients with 
PC-T2D. However, this must be confirmed in follow-up proteomic experiments. PC-T2D 
patients also experienced a rapid and early downregulation of T1R2, and the potential 
uncoupling of SGLT-1 regulation from luminal sweet sensing. This was supported by 
evidence of increased glucose absorption and GIP secretion in patients with PC-T2D, along 
with the absence of an augmented, and potentially compensatory, GLP-1 secretion, which 
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occurred in patients with WC-T2D. Overall, postprandial hyperglycaemia in patients with 
PC-T2D may arise due to enhanced glucose absorption and an altered, GIP-led incretin 
response that fails to adequately stimulate insulin release, all of which may occur secondary 
to impaired sensing of luminal glucose by duodenal T1R2. This is in line with previous 
studies of morbidly obese humans, in which associations emerged between enhanced 
glucose absorption and the augmented secretion of glucagon and GIP, but reduced GLP-1, 
contributing to observed hyperglycaemia208. However, whether enhanced glucose absorption 
in PC-T2D is associated with attenuated glucagon suppression is unknown, and will form 
the basis of future analysis. Investigation of this system in PC-T2D under hyperglycaemic 
conditions will be necessary, to elucidate the influence of prevailing glycaemia on this 
system, as well as reflecting a more physiological state for PC-T2D patients. 
 
Future investigations should also investigate whether non-caloric (i.e., ‘artificial’) 
sweeteners produce similar results. Animal studies have shown that non-caloric sweeteners 
activate STRs, and upregulate SGLT-1 expression in several species29,58,65. The use of 
non-caloric ‘artificial’ sweeteners, particularly in diet beverages, is emerging as a key 
contributor to the rising incidence of T2D, particularly amongst Western populations109. 
Importantly, while sweeteners such as sucralose, aspartame and acesulfame-K were 
originally marketed as suitable calorie-free sugar substitutes, particularly for those with 
T2D110, these animal studies provide evidence that these substances may not be 
metabolically inert, and under conditions of high intake, may worsen glycaemic control.  
 
Limitations 
There were limitations to these studies which must be considered in data interpretation. First, 
the time frame of ID infusion of both Intralipid® and glucose was based on previous studies 
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which used ID glucose to examine intestinal regulation of STRs1,61. We cannot, therefore, 
exclude the possibility that transcriptional changes may occur further into the postprandial 
period. Secondly, the changes in mRNA expression in response to either lipid or glucose 
may not necessarily correlate with changes in cell-surface protein, and as such, proteomics 
will be a critical focus of future investigations. Due to the inconsistent quality of commercial 
antibodies targeting GPRs in pilot protein expression experiments (Western blots) through 
my candidature, the decision to commit regular protein experiments was postponed. Finally, 
the use of habitual dietary questionnaires to establish dietary consumption patterns is 
inherently flawed, as they do not determine acute consumption prior to the study, and intakes 
are commonly underreported by obese individuals187. Future studies in which diets are 
controlled are clearly needed. Despite these limitations, the studies presented in this thesis 
provide novel insights into intestinal nutrient sensing mechanisms, and open up new 
pathways of investigation. 
 
In conclusion, the studies presented in this thesis provide important new knowledge to the 
field of intestinal nutrient sensing. Study findings have the potential to direct future 
investigations to establish the basis of functional connections between luminal nutrient 
sensing, GI hormone secretion and subsequent regulation of energy intake and glycaemia. 
These intestinal nutrient sensors for fats and carbohydrates represent a unique system that 
could be strategically targeted to re-establish energy, and glycaemic homeostasis in 
conditions such as obesity and T2D. The development of specific therapeutic interventions 
that capitalise on their unique localisation and distribution within the GI tract, hold the 
potential for less-invasive and more targeted therapies than those currently available, for the 
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